WO2021108628A1 - Substituted macrocyclic compounds and related methods of treatment - Google Patents

Substituted macrocyclic compounds and related methods of treatment Download PDF

Info

Publication number
WO2021108628A1
WO2021108628A1 PCT/US2020/062320 US2020062320W WO2021108628A1 WO 2021108628 A1 WO2021108628 A1 WO 2021108628A1 US 2020062320 W US2020062320 W US 2020062320W WO 2021108628 A1 WO2021108628 A1 WO 2021108628A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
another embodiment
ring
compound
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2020/062320
Other languages
English (en)
French (fr)
Inventor
Lewis D. Pennington
Younggi Choi
Hoan Huynh
Brian M. Aquila
Ingo Mugge
Yuan HU
James R. Woods
Roman A. Valiulin
Brian Kenneth Raymer
Jorg Martin BENTZIEN
Michael R. Hale
Jonathan Ward LEHMANN
Daljit MATHARU
Srinivasa Karra
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alkermes Inc
Original Assignee
Alkermes Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to MX2022006206A priority Critical patent/MX2022006206A/es
Priority to ES20828463T priority patent/ES3041424T3/es
Priority to CN202080081320.8A priority patent/CN114761412B/zh
Priority to EP25195771.8A priority patent/EP4628167A3/en
Priority to AU2020394444A priority patent/AU2020394444B2/en
Priority to DK20828463.8T priority patent/DK4065585T3/da
Priority to KR1020227021501A priority patent/KR20220106793A/ko
Priority to IL293240A priority patent/IL293240B2/en
Priority to EP20828463.8A priority patent/EP4065585B1/en
Priority to JP2022529454A priority patent/JP7787812B2/ja
Priority to SI202030661T priority patent/SI4065585T1/sl
Priority to MDE20221089T priority patent/MD4065585T2/ro
Priority to FIEP20828463.8T priority patent/FI4065585T3/fi
Priority to MA57908A priority patent/MA57908B1/fr
Priority to RS20250911A priority patent/RS67202B1/sr
Application filed by Alkermes Inc filed Critical Alkermes Inc
Priority to LTEPPCT/US2020/062320T priority patent/LT4065585T/lt
Priority to IL320038A priority patent/IL320038A/en
Priority to CA3155885A priority patent/CA3155885A1/en
Priority to SM20250340T priority patent/SMT202500340T1/it
Priority to HRP20251156TT priority patent/HRP20251156T1/hr
Priority to NZ787541A priority patent/NZ787541B2/en
Priority to BR112022009938A priority patent/BR112022009938A2/pt
Publication of WO2021108628A1 publication Critical patent/WO2021108628A1/en
Priority to SA522432691A priority patent/SA522432691B1/ar
Anticipated expiration legal-status Critical
Priority to ZA2022/06482A priority patent/ZA202206482B/en
Priority to AU2025203295A priority patent/AU2025203295A1/en
Priority to JP2025141156A priority patent/JP2025186272A/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Definitions

  • the present invention relates to substituted macrocyclic compounds, particularly, substituted macrocyclic compounds having agonist activity.
  • Orexin is a neuropeptide synthesized and released by a subpopulation of neurons within the lateral hypothalamus and its surrounding regions. It consists of two subtypes: orexin A and orexin B. Orexin A and orexin B bind to orexin receptors. Orexin receptors are G protein-coupled receptors expressed preferentially in the brain. There are two subtypes (type 1 and type 2) of orexin receptors (Cell, Vol. 92, 573-585, 1998).
  • Activation of orexin receptors is known to be important for a variety of central nervous system functions, such as maintenance of wakefulness, energy homeostasis, reward processing and motivation (Saper et al, TRENDS in Neuroscience 2001; Yamanaka et al, Neuron 2003; Sakurai, Nature Reviews Neuroscience 2014).
  • Narcolepsy is a neurological disease that results in excessive daytime sleepiness, sudden bouts of muscular paralysis (cataplexy), and disrupted sleep patterns (Mahoney et al. , Nature Reviews Neuroscience, 2019). It is known that narcolepsy is caused by the degeneration of orexin neurons. Narcoleptic symptoms can be modeled in transgenic mice engineered to degenerate orexin neurons, and their symptoms can be reversed by intraventricular administration of orexin peptides (Proc. Natl Acad. Sci. USA, Vol. 101, 4649-4654, 2004). Studies of orexin-2 receptor knockout mice have suggested that the orexin-2 receptor plays a preferential role in maintaining wakefulness (Cell, Vol.
  • orexin-2 receptor agonists can be therapeutic agents for narcolepsy or other disorders exhibiting excessive daytime sleepiness, such as Parkinson’s disease (CNS Drugs, Vol. 27, 83-90, 2013; Brain, Vol. 130, 2007, 1586- 1595).
  • a compound having agonist activity at the orexin-2 receptor is hypothesized to be useful as a novel therapeutic agent for narcolepsy, idiopathic hypersomnia, hypersomnia, sleep apnea syndrome, disturbance of consciousness such as coma and the like, narcolepsy syndrome, hypersomnolence syndrome characterized by hypersomnia (e.g., in Parkinson’s disease, Guillain-Barre syndrome or Kleine Levin syndrome), Alzheimer’s disease, obesity, insulin resistance syndrome, cardiac failure, diseases related to bone loss, or sepsis and the like.
  • hypersomnia e.g., in Parkinson’s disease, Guillain-Barre syndrome or Kleine Levin syndrome
  • Alzheimer’s disease e.g., in Parkinson’s disease, Guillain-Barre syndrome or Kleine Levin syndrome
  • Alzheimer’s disease e.g., in Parkinson’s disease, Guillain-Barre syndrome or Kleine Levin syndrome
  • Alzheimer’s disease e.g
  • the present invention aims to provide substituted macrocyclic compounds having orexin-2 receptor agonist activity.
  • the present invention provides a compound represented by Formula I-A or a pharmaceutically acceptable salt thereof:
  • ring A is selected from the group consisting of phenyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, and triazinyl; n is 1, 2, or 3;
  • T is CR1R2 or O
  • W is CR4R5 or O
  • U is CR6R7
  • X is CR8R9
  • V is CR 3 orN
  • Y is NR10, O or absent
  • Z is (CRi 2 Ri3) m ;
  • R is halogen or deuterium; and p is 0, 1, 2, 3, or 4; and further wherein: m is 1, 2, 3, or 4;
  • Ri, R2, R4, and R5 are each, independently, selected from the group consisting of H, halogen, and deuterium; or, alternatively, R2 and R5 together with the carbon atoms to which they are attached, form a single bond;
  • R 3 is selected from the group consisting of H, deuterium, halogen, hydroxyl, and cyano; or, alternatively, R 3 and Ri, together with the carbon atoms to which they are attached, form a C 3 -Cs cycloalkyl; or, alternatively, R3 and R4, together with the carbon atoms to which they are attached, form a C3-C5 cycloalkyl;
  • R6, R7, Re, R9, and R11 are each, independently, selected from the group consisting of H, halogen, and deuterium;
  • Rio is selected from the group consisting of H, unsubstituted Ci-C3alkyl, and Ci- C3alkyl substituted with one or more halogen atoms; and each R12 and R13 is, independently, selected from the group consisting of H, halogen, deuterium, unsubstituted Ci-C3alkyl, and Ci-C3alkyl substituted with one or more halogen atoms.
  • ring A is selected from the group consisting of phenyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, and triazinyl; n is 1, 2, or 3;
  • T is CR1R2 or O
  • W is CR4R5 or O
  • U is CR6R7;
  • X is CRsRo;
  • V is CR3 orN
  • Y is NR10, O or absent
  • Z is (CRi 2 Ri3) m ;
  • R is halogen or deuterium; and p is 0, 1, 2, 3, or 4; and further wherein: m is 1, 2, 3, or 4;
  • Ri, R2, R4, and Rs are each, independently, selected from the group consisting of H, halogen, and deuterium; or, alternatively, R2 and R5 together with the carbon atoms to which they are attached, form a single bond;
  • R3 is selected from the group consisting of H, deuterium, halogen, hydroxyl, and cyano; or, alternatively, R3 and Ri, together with the carbon atoms to which they are attached, form a C3-C5 cycloalkyl; or, alternatively, R3 and R4, together with the carbon atoms to which they are attached, form a C3-C5 cycloalkyl;
  • R6, R7, Re, R9, and R11 are each, independently, selected from the group consisting of H, halogen, and deuterium;
  • Rio is selected from the group consisting of H, unsubstituted Ci-C3alkyl, and Ci- C3alkyl substituted with one or more halogen atoms; and each R12 and R13 is, independently, selected from the group consisting of H, halogen, deuterium, unsubstituted Ci-C3alkyl, and Ci-C3alkyl substituted with one or more halogen atoms.
  • ring A is selected from the group consisting of phenyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, and triazinyl; n is 1, 2, or 3;
  • T is CR1R2 or O
  • W is CR4R5 or O
  • U is CR6R7
  • X is CR8R9
  • V is CR3 orN
  • Y is NR10, O or absent
  • Z is (CRi 2 Ri3) m ;
  • R is halogen or deuterium; and p is 0, 1, 2, 3, or 4; and further wherein: m is 2, 3, 4, or 5 when Y is absent; or m is 1, 2, 3, or 4 when Y is NR10 or O;
  • Ri, R2, R4, and R5 are each, independently, selected from the group consisting of H, halogen, and deuterium; or, alternatively, R2 and R5 together with the carbon atoms to which they are attached, form a single bond;
  • R 3 is selected from the group consisting of H, deuterium, halogen, hydroxyl, and cyano; or, alternatively, R 3 and Ri, together with the carbon atoms to which they are attached, form a C 3 -Cs cycloalkyl; or, alternatively, R 3 and R4, together with the carbon atoms to which they are attached, form a C 3 -Cs cycloalkyl;
  • R6, R7, Re, R9, and R11 are each, independently, selected from the group consisting of H, halogen, and deuterium;
  • Rio is selected from the group consisting of H, unsubstituted Ci-C 3 alkyl, and Ci- Cbalkyl substituted with one or more halogen atoms; and each R12 and RI 3 is, independently, selected from the group consisting of H, halogen, deuterium, unsubstituted Ci-C 3 alkyl, and Ci-C 3 alkyl substituted with one or more halogen atoms.
  • ring A is selected from the group consisting of phenyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, and triazinyl; n is 1, 2, or 3;
  • T is CR1R2 or O
  • W is CR4R5 or O; U is CReR?;
  • X is CR8R9
  • V is CR 3 orN
  • Y is NR10, O or absent
  • Z is (CRi 2 Ri3) m ;
  • R is halogen or deuterium; and p is 0, 1, 2, 3, or 4; and further wherein: m is 2, 3, 4, or 5 when Y is absent; or m is 1, 2, 3, or 4 when Y is NR10 or O;
  • Ri, R2, R4, and R5 are each, independently, selected from the group consisting of H, halogen, and deuterium; or, alternatively, R2 and R5 together with the carbon atoms to which they are attached, form a single bond;
  • R.3 is selected from the group consisting of H, deuterium, halogen, hydroxyl, and cyano; or, alternatively, R.3 and Ri, together with the carbon atoms to which they are attached, form a C3-C5 cycloalkyl; or, alternatively, R3 and R4, together with the carbon atoms to which they are attached, form a C3-C5 cycloalkyl;
  • R6, R7, Re, R9, and R11 are each, independently, selected from the group consisting of H, halogen, and deuterium;
  • Rio is selected from the group consisting of H, unsubstituted Ci-C3alkyl, and Ci- C3alkyl substituted with one or more halogen atoms; and each R12 and R13 is, independently, selected from the group consisting of H, halogen, deuterium, unsubstituted Ci-C3alkyl, and Ci-C3alkyl substituted with one or more halogen atoms.
  • composition comprising a compound of any of Formula I-A, I, II- A, or II, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
  • a method of treating narcolepsy in a subject in need thereof comprising administering to the subject a compound of Formula I-A, I, II-A, or II, or a pharmaceutically acceptable salt thereof.
  • provided herein is a method of treating cataplexy in a subject in need thereof comprising administering to the subject a compound of Formula I-A, I, II-A, or II, or a pharmaceutically acceptable salt thereof.
  • compounds e.g., the compounds of Formula I-A, I, II-A, or II, or pharmaceutically acceptable salts thereof, that are useful in the treatment of narcolepsy or cataplexy in a subject.
  • these compounds may modulate the orexin-2 receptor.
  • the compounds provided herein are considered orexin-2 agonists.
  • the compounds provided herein are useful in treatment of narcolepsy in a subject by acting as an agonist of the orexin-2 receptor. Definitions
  • the articles “a” and “an” refer to one or to more than one (i.e., to at least one) of the grammatical object of the article.
  • an element means one element or more than one element.
  • use of the term “including” as well as other forms, such as “include,” “includes,” and “included,” is not limiting.
  • the term “about” will be understood by persons of ordinary skill in the art and will vary to some extent on the context in which it is used. As used herein when referring to a measurable value such as an amount, a temporal duration, and the like, the term “about” is meant to encompass variations of ⁇ 20% or ⁇ 10%, including ⁇ 5%, ⁇ 1%, and ⁇ 0.1% from the specified value, as such variations are appropriate to perform the disclosed methods.
  • ECrio refers to the concentration of a compound required to achieve an effect that is 50% of the maximal observed effect of a compound.
  • agonist refers to a compound that, when contacted with a target of interest (e.g., the orexin-2 receptor), causes an increase in the magnitude of a certain activity or function of the target compared to the magnitude of the activity or function observed in the absence of the agonist.
  • a target of interest e.g., the orexin-2 receptor
  • treat includes the diminishment or alleviation of at least one symptom associated or caused by the state, disorder or disease being treated.
  • the treatment comprises bringing into contact with the orexin-2 receptor an effective amount of a compound of the invention for conditions related to narcolepsy or cataplexy.
  • the term “prevent” or “prevention” means no disorder or disease development if none had occurred, or no further disorder or disease development if there had already been development of the disorder or disease. Also considered is the ability of one to prevent some or all of the symptoms associated with the disorder or disease.
  • the term “patient,” “individual” or “subject” refers to a human or a non-human mammal. Non-human mammals include, for example, livestock and pets, such as ovine, bovine, porcine, canine, feline and murine mammals. Preferably, the patient, subject, or individual is human.
  • the terms “effective amount,” “pharmaceutically effective amount,” and “therapeutically effective amount” refer to a nontoxic but sufficient amount of an agent to provide the desired biological result. That result may be reduction or alleviation of the signs, symptoms, or causes of a disease, or any other desired alteration of a biological system. An appropriate therapeutic amount in any individual case may be determined by one of ordinary skill in the art using routine experimentation.
  • the term “pharmaceutically acceptable” refers to a material, such as a carrier or diluent, which does not abrogate the biological activity or properties of the compound, and is relatively non-toxic, i.e., the material may be administered to an individual without causing undesirable biological effects or interacting in a deleterious manner with any of the components of the composition in which it is contained.
  • the term “pharmaceutically acceptable salt” refers to derivatives of the disclosed compounds wherein the parent compound is modified by converting an existing acid or base moiety to its salt form.
  • pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like.
  • the pharmaceutically acceptable salts of the present invention include the conventional non-toxic salts of the parent compound formed, for example, from non-toxic inorganic or organic acids.
  • the pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods.
  • such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred.
  • pharmaceutically acceptable salt is not limited to a mono, or 1 : 1, salt.
  • “pharmaceutically acceptable salt” also includes bis-salts, such as a bis-hydrochloride salt. Lists of suitable salts are found in Remington’s Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pa., 1985, p.
  • composition refers to a mixture of at least one compound useful within the invention with a pharmaceutically acceptable carrier.
  • the pharmaceutical composition facilitates administration of the compound to a patient or subject. Multiple techniques of administering a compound exist in the art including, but not limited to, intravenous, oral, aerosol, parenteral, ophthalmic, pulmonary, and topical administration.
  • the term “pharmaceutically acceptable carrier” means a pharmaceutically acceptable material, composition or carrier, such as a liquid or solid filler, stabilizer, dispersing agent, suspending agent, diluent, excipient, thickening agent, solvent or encapsulating material, involved in carrying or transporting a compound useful within the invention within or to the patient such that it may perform its intended function.
  • a pharmaceutically acceptable material, composition or carrier such as a liquid or solid filler, stabilizer, dispersing agent, suspending agent, diluent, excipient, thickening agent, solvent or encapsulating material, involved in carrying or transporting a compound useful within the invention within or to the patient such that it may perform its intended function.
  • Such constructs are carried or transported from one organ, or portion of the body, to another organ, or portion of the body.
  • Each carrier must be “acceptable” in the sense of being compatible with the other ingredients of the formulation, including the compound useful within the invention, and not injurious to the patient.
  • materials that may serve as pharmaceutically acceptable carriers include: sugars, such as lactose, glucose and sucrose; starches, such as com starch and potato starch; cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients, such as cocoabutter and suppository waxes; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, com oil and soybean oil; glycols, such as propylene glycol; polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffering agents, such as magnesium hydroxide and aluminum hydroxide; surface active agents; alginic acid; pyrogen-free water; isotonic cellulose,
  • “pharmaceutically acceptable carrier” also includes any and all coatings, antibacterial and antifungal agents, and absorption delaying agents, and the like that are compatible with the activity of the compound useful within the invention and are physiologically acceptable to the patient. Supplementary active compounds may also be incorporated into the compositions.
  • the “pharmaceutically acceptable carrier” may further include a pharmaceutically acceptable salt of the compound useful within the invention.
  • alkyl by itself or as part of another substituent means, unless otherwise stated, a straight or branched chain hydrocarbon having the number of carbon atoms designated (i.e., Ci-6 alkyl means an alkyl having one to six carbon atoms) and includes straight and branched chains. Examples include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert- butyl, pentyl, neopentyl, and hexyl. Other examples of Ci-C6-alkyl include ethyl, methyl, isopropyl, isobutyl, n-pentyl, and n-hexyl.
  • halo or “halogen” alone or as part of another substituent means, unless otherwise stated, a fluorine, chlorine, bromine, or iodine atom, preferably, fluorine, chlorine, or bromine, more preferably, fluorine or chlorine.
  • substituted means that an atom or group of atoms has replaced hydrogen as the substituent attached to another group.
  • the present invention provides a compound represented by Formula I-A or a pharmaceutically acceptable salt thereof: wherein: ring A is selected from the group consisting of phenyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, and triazinyl; n is 1, 2, or 3;
  • T is CR1R2 or O
  • W is CR4R5 or O
  • U is CR6R7
  • X is CR8R9
  • V is CR 3 orN
  • Y is NR10, O or absent
  • Z is (CRi 2 Ri3) m ;
  • R is halogen or deuterium; and p is 0, 1, 2, 3, or 4; and further wherein: m is 1, 2, 3, or 4;
  • Ri, R2, R4, and R5 are each, independently, selected from the group consisting of H, halogen, and deuterium; or, alternatively, R2 and R5 together with the carbon atoms to which they are attached, form a single bond;
  • R 3 is selected from the group consisting of H, deuterium, halogen, hydroxyl, and cyano; or, alternatively, R 3 and Ri, together with the carbon atoms to which they are attached, form a C 3 -Cs cycloalkyl; or, alternatively, R 3 and R4, together with the carbon atoms to which they are attached, form a C 3 -Cs cycloalkyl;
  • R6, R7, Re, R9, and R11 are each, independently, selected from the group consisting of H, halogen, and deuterium;
  • Rio is selected from the group consisting of H, unsubstituted Ci-C 3 alkyl, and Ci- C 3 alkyl substituted with one or more halogen atoms; and each R12 and RI 3 is, independently, selected from the group consisting of H, halogen, deuterium, unsubstituted Ci-C 3 alkyl, and Ci-C 3 alkyl substituted with one or more halogen atoms.
  • a compound of Formula I-A having the structure of Formula I or a pharmaceutically acceptable salt thereof:
  • ring A is selected from the group consisting of phenyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, and triazinyl; n is 1, 2, or 3;
  • T is CR1R2 or O
  • W is CR4R5 or O
  • U is CR6R7
  • X is CR8R9; V is CR3 or N;
  • Y is NR10, O or absent
  • Z is (CRi 2 Ri3) m ;
  • R is halogen or deuterium; and p is 0, 1, 2, 3, or 4; and further wherein: m is 1, 2, 3, or 4;
  • Ri, R2, R4, and R5 are each, independently, selected from the group consisting of H, halogen, and deuterium; or, alternatively, R2 and R5 together with the carbon atoms to which they are attached, form a single bond;
  • R3 is selected from the group consisting of H, deuterium, halogen, hydroxyl, and cyano; or, alternatively, R3 and Ri, together with the carbon atoms to which they are attached, form a C3-C5 cycloalkyl; or, alternatively, R3 and R4, together with the carbon atoms to which they are attached, form a C3-C5 cycloalkyl;
  • R6, R7, Re, R9, and R11 are each, independently, selected from the group consisting of H, halogen, and deuterium;
  • Rio is selected from the group consisting of H, unsubstituted Ci-C3alkyl, and Ci- C3alkyl substituted with one or more halogen atoms; and each R12 and R13 is, independently, selected from the group consisting of H, halogen, deuterium, unsubstituted Ci-C3alkyl, and Ci-C3alkyl substituted with one or more halogen atoms.
  • n is 1. In another embodiment of Formula (I), n is 2. In another embodiment of Formula (I), n is 3.
  • ring A is phenyl. In another embodiment of Formula (I), ring A is pyridinyl. In another embodiment of Formula (I), ring A is pyridazinyl. In another embodiment of Formula (I), ring A is pyrimidinyl. In another embodiment of Formula (I), ring A is pyrazinyl. In another embodiment of Formula (I), ring A is triazinyl.
  • Y is NR10. In another embodiment of Formula (I), Y is O. In another embodiment of Formula (I), Y is absent. In another embodiment of Formula (I), ring A is phenyl and Y is NR10. In another embodiment of Formula (I), ring A is phenyl and Y is O. In another embodiment of Formula (I), ring A is phenyl and Y is absent. In another embodiment of Formula (I), ring A is pyridinyl and Y is NR10. In another embodiment of Formula (I), ring A is pyridinyl and Y is O. In another embodiment of Formula (I), ring A is pyridinyl and Y is absent.
  • ring A is pyridazinyl and Y is NR10. In another embodiment of Formula (I), ring A is pyridazinyl and Y is O. In another embodiment of Formula (I), ring A is pyridazinyl and Y is absent. In another embodiment of Formula (I), ring A is pyrimidinyl and Y is NR10. In another embodiment of Formula (I), ring A is pyrimidinyl and Y is O. In another embodiment of Formula (I), ring A is pyrimidinyl and Y is absent. In another embodiment of Formula (I), ring A is pyrazinyl and Y is NR10.
  • ring A is pyrazinyl and Y is O. In another embodiment of Formula (I), ring A is pyrazinyl and Y is absent. In another embodiment of Formula (I), ring A is triazinyl and Y is NR10. In another embodiment of Formula (I), ring A is triazinyl and Y is O. In another embodiment of Formula (I), ring A is triazinyl and Y is absent.
  • T is CR1R2.
  • T is O.
  • W is CR4R5. In another embodiment of Formula (I), W is O. In another embodiment of Formula (I), T is CR1R2 and W is CR4R5. In another embodiment of Formula (I), T is O and W is CR4R5. In another embodiment of Formula (I), T is CR1R2 and W is O.
  • V is CR3. In another embodiment of Formula (I), V is N.
  • T is CR1R2 and V is CR3. In another embodiment of Formula (I), T is O and V is CR3. In another embodiment of Formula (I), T is CR1R2 and V is N. In another embodiment of Formula (I), T is O and V is N.
  • W is CR4R5 and V is CR3. In another embodiment of Formula (I), W is O and V is CR3. In another embodiment of Formula (I), W is CR4R5 and V is N. In another embodiment of Formula (I), W is O and V is N.
  • T is CR1R2, W is CR4R5, and V is CR3.
  • T is CR1R2, W is O, and V is CR3.
  • T is CR1R2, W is CR4R5, and V is N.
  • T is CR1R2, W is O, and V is N.
  • T is O, W is CR4R5, and V is CR3.
  • m is 1. In another embodiment of Formula (I), m is 2. In another embodiment of Formula (I), m is 3. In another embodiment of Formula (I), m is 4. In another embodiment of Formula (I), m is 1, 2 or 3. In another embodiment of Formula (I), m is 2, 3, or 4. In another embodiment of Formula (I), m is 1 or 2. In another embodiment of Formula (I), m is 3 or 4.
  • Y is O and m is 1. In another embodiment of Formula (I), Y is O and m is 2. In another embodiment of Formula (I), Y is O and m is 3. In another embodiment of Formula (I), Y is O and m is 4. In another embodiment of Formula (I), Y is O and m is 1, 2, or 3. In another embodiment of Formula (I), Y is O and m is 2, 3, or 4. In another embodiment of Formula (I), Y is O and m is 1 or 2. In another embodiment of Formula (I), Y is O and m is 3 or 4.
  • Y is absent and m is 1. In another embodiment of Formula (I), Y is absent and m is 2. In another embodiment of Formula (I), Y is absent and m is 3. In another embodiment of Formula (I), Y is absent and m is 4. In another embodiment of Formula (I), Y is absent and m is 1, 2, or 3. In another embodiment of Formula (I), Y is absent and m is 2, 3, or 4. In another embodiment of Formula (I), Y is absent and m is 1 or 2. In another embodiment of Formula (I), Y is absent and m is 3 or 4.
  • Y is NRio and m is 1. In another embodiment of Formula (I), Y is NRio and m is 2. In another embodiment of Formula (I), Y is NRio and m is 3. In another embodiment of Formula (I), Y is NRio and m is 4. In another embodiment of Formula (I), Y is NRio and m is 1, 2, or 3. In another embodiment of Formula (I), Y is NRio and m is 2, 3, or 4. In another embodiment of Formula (I), Y is NRio and m is 1 or 2.
  • Y is NRio and m is 3 or 4.
  • ring A is phenyl and n is 1. In another embodiment of Formula (I), ring A is phenyl and n is 2. In another embodiment of Formula (I), ring A is phenyl and n is 3. In another embodiment of Formula (I), ring A is pyridinyl and n is 1. In another embodiment of Formula (I), ring A is pyridinyl and n is 2. In another embodiment of Formula (I), ring A is pyridinyl and n is 3. In another embodiment of Formula (I), ring A is pyridazinyl and n is 1. In another embodiment of Formula (I), ring A is pyridazinyl and n is 2.
  • ring A is pyridazinyl and n is 3. In another embodiment of Formula (I), ring A is pyrimidinyl and n is 1. In another embodiment of Formula (I), ring A is pyrimidinyl and n is 2. In another embodiment of Formula (I), ring A is pyrimidinyl and n is 3. In another embodiment of Formula (I), ring A is pyrazinyl and n is 1. In another embodiment of Formula (I), ring A is pyrazinyl and n is 2. In another embodiment of Formula (I), ring A is pyrazinyl and n is 3. In another embodiment of Formula (I), ring A is triazinyl and n is 1. In another embodiment of Formula (I), ring A is triazinyl and n is 2. In another embodiment of Formula (I), ring A is triazinyl and n is 3.
  • ring A is phenyl, n is 1, and Y is NRio. In another embodiment of Formula (I), ring A is phenyl, n is 2, and Y is NRio. In another embodiment of Formula (I), ring A is phenyl, n is 3, and Y is NRio. In another embodiment of Formula (I), ring A is phenyl, n is 1, and Y is O. In another embodiment of Formula (I), ring A is phenyl, n is 2, and Y is O. In another embodiment of Formula (I), ring A is phenyl, n is 3, and Y is O.
  • ring A is phenyl, n is 1, and Y is absent. In another embodiment of Formula (I), ring A is phenyl, n is 2, and Y is absent. In another embodiment of Formula (I), ring A is phenyl, n is 3, and Y is absent.
  • ring A is phenyl, n is 1, Y is NRio, and m is 1 or 2. In another embodiment of Formula (I), ring A is phenyl, n is 2, Y is NRio, and m is 1 or 2. In another embodiment of Formula (I), ring A is phenyl, n is 3, Y is NRio, and m is 1 or 2. In another embodiment of Formula (I), ring A is phenyl, n is 1, Y is O, and m is 1 or 2. In another embodiment of Formula (I), ring A is phenyl, n is 2, Y is O, and m is 1 or 2.
  • ring A is phenyl, n is 3, Y is O, and m is 1 or 2.
  • ring A is phenyl, n is 1, Y is absent, and m is 1 or 2.
  • ring A is phenyl, n is 2, Y is absent, and m is 1 or 2.
  • ring A is phenyl, n is 3, Y is absent, and m is 1 or 2.
  • ring A is phenyl, n is 1, Y is NRio, and m is 3 or 4.
  • ring A is phenyl, n is 2, Y is NRio, and m is 3 or 4. In another embodiment of Formula (I), ring A is phenyl, n is 3, Y is NRio, and m is 3 or 4. In another embodiment of Formula (I), ring A is phenyl, n is 1, Y is O, and m is 3 or 4. In another embodiment of Formula (I), ring A is phenyl, n is 2, Y is O, and m is 3 or 4. In another embodiment of Formula (I), ring A is phenyl, n is 3, Y is O, and m is 3 or 4.
  • ring A is phenyl, n is 1, Y is absent, and m is 3 or 4. In another embodiment of Formula (I), ring A is phenyl, n is 2, Y is absent, and m is 3 or 4. In another embodiment of Formula (I), ring A is phenyl, n is 3, Y is absent, and m is 3 or 4.
  • ring A is pyridinyl, n is 1, and Y is NRio.
  • ring A is pyridinyl, n is 2, and Y is NRio.
  • ring A is pyridinyl, n is 3, and Y is NRio.
  • ring A is pyridinyl, n is 1, and Y is O.
  • ring A is pyridinyl, n is 2, and Y is O.
  • ring A is pyridinyl, n is 3, and Y is O.
  • ring A is pyridinyl, n is 1, and Y is absent. In another embodiment of Formula (I), ring A is pyridinyl, n is 2, and Y is absent. In another embodiment of Formula (I), ring A is pyridinyl, n is 3, and Y is absent.
  • ring A is pyridinyl, n is 1, Y is NRio, and m is 1 or 2. In another embodiment of Formula (I), ring A is pyridinyl, n is 2, Y is NRio, and m is 1 or 2. In another embodiment of Formula (I), ring A is pyridinyl, n is 3, Y is NRio, and m is 1 or 2. In another embodiment of Formula (I), ring A is pyridinyl, n is 1, Y is O, and m is 1 or 2. In another embodiment of Formula (I), ring A is pyridinyl, n is 2, Y is O, and m is 1 or 2. In another embodiment of Formula (I), ring A is pyridinyl, n is 3, Y is O, and m is 1 or 2. In another embodiment of Formula (I), ring A is pyridinyl, n is 3, Y is O, and m is 1 or 2.
  • ring A is pyridinyl, n is 1, Y is absent, and m is 1 or 2.
  • ring A is pyridinyl, n is 2, Y is absent, and m is 1 or 2.
  • ring A is pyridinyl, n is 3, Y is absent, and m is 1 or 2.
  • ring A is pyridinyl, n is 1, Y is NRio, and m is 3 or 4. In another embodiment of Formula (I), ring A is pyridinyl, n is 2, Y is NRio, and m is 3 or 4. In another embodiment of Formula (I), ring A is pyridinyl, n is 3, Y is NRio, and m is 3 or 4. In another embodiment of Formula (I), ring A is pyridinyl, n is 1, Y is O, and m is 3 or 4. In another embodiment of Formula (I), ring A is pyridinyl, n is 2, Y is O, and m is 3 or 4.
  • ring A is pyridinyl, n is 3, Y is O, and m is 3 or 4. In another embodiment of Formula (I), ring A is pyridinyl, n is 1, Y is absent, and m is 3 or 4.
  • ring A is pyridinyl, n is 2, Y is absent, and m is 3 or 4. In another embodiment of Formula (I), ring A is pyridinyl, n is 3, Y is absent, and m is 3 or 4.
  • ring A is pyridazinyl, n is 1, and Y is NRio.
  • ring A is pyridazinyl, n is 2, and Y is NRio.
  • ring A is pyridazinyl, n is 3, and Y is NRio.
  • ring A is pyridazinyl, n is 1, and Y is O.
  • ring A is pyridazinyl, n is 2, and Y is O.
  • ring A is pyridazinyl, n is 3, and Y is O. In another embodiment of Formula (I), ring A is pyridazinyl, n is 1, and Y is absent. In another embodiment of Formula (I), ring A is pyridazinyl, n is 2, and Y is absent. In another embodiment of Formula (I), ring A is pyridazinyl, n is 3, and Y is absent.
  • ring A is pyridazinyl, n is 1, Y is NRio, and m is 1 or 2. In another embodiment of Formula (I), ring A is pyridazinyl, n is 2, Y is NRio, and m is 1 or 2. In another embodiment of Formula (I), ring A is pyridazinyl, n is 3, Y is NRio, and m is 1 or 2. In another embodiment of Formula (I), ring A is pyridazinyl, n is 1, Y is O, and m is 1 or 2.
  • ring A is pyridazinyl, n is 2, Y is O, and m is 1 or 2. In another embodiment of Formula (I), ring A is pyridazinyl, n is 3, Y is O, and m is 1 or 2. In another embodiment of Formula (I), ring A is pyridazinyl, n is 1, Y is absent, and m is 1 or 2. In another embodiment of Formula (I), ring A is pyridazinyl, n is 2,
  • Y is absent, and m is 1 or 2.
  • ring A is pyridazinyl, n is 3, Y is absent, and m is 1 or 2.
  • ring A is pyridazinyl, n is 1, Y is NRio, and m is 3 or 4.
  • ring A is pyridazinyl, n is 2, Y is NRio, and m is 3 or 4.
  • ring A is pyridazinyl, n is 3, Y is NRio, and m is 3 or 4.
  • ring A is pyridazinyl, n is 1, Y is O, and m is 3 or 4. In another embodiment of Formula (I), ring A is pyridazinyl, n is 2, Y is O, and m is 3 or 4. In another embodiment of Formula (I), ring A is pyridazinyl, n is 3, Y is O, and m is 3 or 4. In another embodiment of Formula (I), ring A is pyridazinyl, n is 1, Y is absent, and m is 3 or 4. In another embodiment of Formula (I), ring A is pyridazinyl, n is 2, Y is absent, and m is 3 or 4. In another embodiment of Formula (I), ring A is pyridazinyl, n is 3, Y is absent, and m is 3 or 4. In another embodiment of Formula (I), ring A is pyridazinyl, n is 3, Y is absent, and m is 3 or 4. In another embodiment
  • ring A is pyrimidinyl, n is 1, and Y is NRio.
  • ring A is pyrimidinyl, n is 2, and Y is NRio. In another embodiment of Formula (I), ring A is pyrimidinyl, n is 3, and Y is NRio. In another embodiment of Formula (I), ring A is pyrimidinyl, n is 1, and Y is O. In another embodiment of Formula (I), ring A is pyrimidinyl, n is 2, and Y is O. In another embodiment of Formula (I), ring A is pyrimidinyl, n is 3, and Y is O. In another embodiment of Formula (I), ring A is pyrimidinyl, n is 1, and Y is absent. In another embodiment of Formula (I), ring A is pyrimidinyl, n is 2, and Y is absent. In another embodiment of Formula (I), ring A is pyrimidinyl, n is 3, and Y is absent.
  • ring A is pyrimidinyl, n is 1, Y is NRio, and m is 1 or 2. In another embodiment of Formula (I), ring A is pyrimidinyl, n is 2, Y is NRio, and m is 1 or 2. In another embodiment of Formula (I), ring A is pyrimidinyl, n is 3, Y is NRio, and m is 1 or 2. In another embodiment of Formula (I), ring A is pyrimidinyl, n is 1, Y is O, and m is 1 or 2. In another embodiment of Formula (I), ring A is pyrimidinyl, n is 2, Y is O, and m is 1 or 2.
  • ring A is pyrimidinyl, n is 3, Y is O, and m is 1 or 2.
  • ring A is pyrimidinyl, n is 1, Y is absent, and m is 1 or 2.
  • ring A is pyrimidinyl, n is 2, Y is absent, and m is 1 or 2.
  • ring A is pyrimidinyl, n is 3, Y is absent, and m is 1 or 2.
  • ring A is pyrimidinyl, n is 1, Y is NRio, and m is 3 or 4.
  • ring A is pyrimidinyl, n is 2, Y is NRio, and m is 3 or 4. In another embodiment of Formula (I), ring A is pyrimidinyl, n is 3, Y is NRio, and m is 3 or 4. In another embodiment of Formula (I), ring A is pyrimidinyl, n is 1, Y is O, and m is 3 or 4. In another embodiment of Formula (I), ring A is pyrimidinyl, n is 2, Y is O, and m is 3 or 4. In another embodiment of Formula (I), ring A is pyrimidinyl, n is 3, Y is O, and m is 3 or 4. In another embodiment of Formula (I), ring A is pyrimidinyl, n is 1, Y is absent, and m is 3 or 4. In another embodiment of Formula (I),
  • ring A is pyrimidinyl, n is 2, Y is absent, and m is 3 or 4.
  • ring A is pyrimidinyl, n is 3, Y is absent, and m is 3 or 4.
  • ring A is pyrazinyl, n is 1, and Y is NRio.
  • ring A is pyrazinyl, n is 2, and Y is NRio.
  • ring A is pyrazinyl, n is 3, and Y is NRio.
  • ring A is pyrazinyl, n is 1, and Y is O.
  • ring A is pyrazinyl, n is 2, and Y is O.
  • ring A is pyrazinyl, n is 3, and Y is O.
  • ring A is pyrazinyl, n is 1, and Y is absent. In another embodiment of Formula (I), ring A is pyrazinyl, n is 2, and Y is absent. In another embodiment of Formula (I), ring A is pyrazinyl, n is 3, and Y is absent.
  • ring A is pyrazinyl, n is 1, Y is NRio, and m is 1 or 2. In another embodiment of Formula (I), ring A is pyrazinyl, n is 2, Y is NRio, and m is
  • ring A is pyrazinyl, n is 3, Y is NRio, and m is
  • ring A is pyrazinyl, n is 1, Y is O, and m is 1 or 2.
  • ring A is pyrazinyl, n is 2, Y is O, and m is 1 or 2.
  • ring A is pyrazinyl, n is 3, Y is O, and m is 1 or 2.
  • ring A is pyrazinyl, n is 1, Y is absent, and m is 1 or 2.
  • ring A is pyrazinyl, n is 2, Y is absent, and m is 1 or 2.
  • ring A is pyrazinyl, n is 3, Y is absent, and m is 1 or 2.
  • ring A is pyrazinyl, n is 1, Y is NRio, and m is
  • ring A is pyrazinyl
  • n is 2
  • Y is NRio
  • m is
  • ring A is pyrazinyl, n is 3, Y is NRio, and m is
  • ring A is pyrazinyl, n is 1, Y is O, and m is 3 or 4.
  • ring A is pyrazinyl, n is 2, Y is O, and m is 3 or 4.
  • ring A is pyrazinyl, n is 3, Y is O, and m is 3 or 4.
  • ring A is pyrazinyl, n is 1, Y is absent, and m is 3 or 4.
  • ring A is pyrazinyl, n is 2, Y is absent, and m is 3 or 4.
  • ring A is pyrazinyl, n is 3, Y is absent, and m is 3 or 4.
  • ring A is pyrazinyl, n is 3, Y is absent, and m is 3 or 4.
  • ring A is pyrazinyl, n is 3, Y is absent, and m is 3 or 4.
  • ring A is triazinyl, n is 1, and Y is NRio. In another embodiment of Formula (I), ring A is triazinyl, n is 2, and Y is NRio. In another embodiment of Formula (I), ring A is triazinyl, n is 3, and Y is NRio. In another embodiment of Formula (I), ring A is triazinyl, n is 1, and Y is O. In another embodiment of Formula (I), ring A is triazinyl, n is 2, and Y is O. In another embodiment of Formula (I), ring A is triazinyl, n is 3, and Y is O.
  • ring A is triazinyl, n is 1, and Y is absent. In another embodiment of Formula (I), ring A is triazinyl, n is 2, and Y is absent. In another embodiment of Formula (I), ring A is triazinyl, n is 3, and Y is absent.
  • ring A is triazinyl, n is 1, Y is NRio, and m is 1 or 2. In another embodiment of Formula (I), ring A is triazinyl, n is 2, Y is NRio, and m is 1 or 2. In another embodiment of Formula (I), ring A is triazinyl, n is 3, Y is NRio, and m is 1 or 2. In another embodiment of Formula (I), ring A is triazinyl, n is 1, Y is O, and m is 1 or 2. In another embodiment of Formula (I), ring A is triazinyl, n is 2, Y is O, and m is 1 or 2.
  • ring A is triazinyl, n is 3, Y is O, and m is 1 or 2.
  • ring A is triazinyl, n is 1, Y is absent, and m is 1 or 2.
  • ring A is triazinyl, n is 2, Y is absent, and m is 1 or 2.
  • ring A is triazinyl, n is 3, Y is absent, and m is 1 or 2.
  • ring A is triazinyl, n is 1, Y is NRio, and m is 3 or 4.
  • ring A is triazinyl, n is 2, Y is NRio, and m is 3 or 4. In another embodiment of Formula (I), ring A is triazinyl, n is 3, Y is NRio, and m is 3 or 4. In another embodiment of Formula (I), ring A is triazinyl, n is 1, Y is O, and m is 3 or 4. In another embodiment of Formula (I), ring A is triazinyl, n is 2, Y is O, and m is 3 or 4. In another embodiment of Formula (I), ring A is triazinyl, n is 3, Y is O, and m is 3 or 4.
  • ring A is triazinyl, n is 1, Y is absent, and m is 3 or 4. In another embodiment of Formula (I), ring A is triazinyl, n is 2, Y is absent, and m is 3 or 4. In another embodiment of Formula (I), ring A is triazinyl, n is 3, Y is absent, and m is 3 or 4.
  • ring A is phenyl
  • T is CR1R2
  • W is CR4R5
  • V is CR3.
  • ring A is phenyl, p is 0, T is CR1R2, W is CR4R5, and V is CR3.
  • ring A is phenyl, T is CR1R2,
  • W is CR4R5, V is CR3, and n is 1.
  • ring A is phenyl, T is CR1R2, W is CR4R5, V is CR3, and n is 2.
  • ring A is CR1R2, W is CR4R5, V is CR3, and n is 3.
  • ring A is phenyl, p is 0, T is CR1R2, W is CR4R5, V is CR3, and n is 1.
  • ring A is phenyl, p is 0, T is CR1R2, W is CR4R5, V is CR3, and n is 2.
  • ring A is phenyl, p is 0, T is CR1R2, W is CR4R5, V is CR3, and n is 2.
  • ring A is phenyl, p is 0, T is CR1R2, W is CR4R5, V is CR3, and n is 2.
  • ring A is phenyl, p is 0, T is
  • V is CR3, and n is 3.
  • ring A is phenyl, T is CR1R2, W is CR4R5, V is CR3, and Y is O.
  • ring A is phenyl, p is 0, T is CR1R2, W is CR4R5, V is CR3, and Y is O.
  • ring A is phenyl, T is CR1R2, W is CR4R5, V is CR3, Y is O, and n is 1.
  • ring A is phenyl, T is CR1R2, W is CR4R5, V is CR3, Y is O, and n is 2.
  • ring A is phenyl, T is CR1R2, W is CR4R5, V is CR3, Y is O, and n is 3.
  • ring A is phenyl, p is 0, T is CR1R2, W is CR4R5, V is CR3, Y is O, and n is 1.
  • ring A is phenyl, p is 0, T is CR1R2, W is CR4R5, V is CR3, Y is O, and n is 2.
  • ring A is phenyl, p is 0, T is CR1R2, W is CR4R5, V is CR3, Y is O, and n is 3.
  • ring A is phenyl, T is CR1R2, W is CR4R5, V is CR3, Y is O, and m is 1 or 2.
  • ring A is phenyl, p is 0, T is CR1R2, W is CR4R5, V is CR3, Y is O, and m is 1 or 2.
  • ring A is phenyl, T is CR1R2, W is CR4R5, V is CR3, Y is O, n is 1, and m is 1 or 2.
  • ring A is phenyl, T is CR1R2, W is CR4R5, V is CR3, Y is O, n is 2, and m is 1 or 2.
  • ring A is phenyl, T is CR1R2, W is CR4R5, V is CR3, Y is O, n is 3, and m is 1 or 2.
  • ring A is phenyl, p is 0, T is CR1R2, W is CR4R5, V is CR3, Y is O, n is 1, and m is 1 or 2.
  • ring A is phenyl, p is 0, T is CR1R2, W is CR4R5, V is CR3, Y is O, n is 2, and m is 1 or 2.
  • ring A is phenyl, p is 0, T is CR1R2, W is CR4R5, V is CR3, Y is O, n is 3, and m is 1 or 2.
  • ring A is phenyl, T is CR1R2, W is CR4R5, V is CR3, Y is O, and m is 3 or 4.
  • ring A is phenyl, p is 0, T is CR1R2, W is CR4R5, V is CR3, Y is O, and m is 3 or 4.
  • ring A is phenyl, T is CR1R2, W is CR4R5, V is CR3, Y is O, n is 1, and m is 3 or 4.
  • ring A is phenyl, T is CR1R2, W is CR4R5, V is CR3, Y is O, n is 2, and m is 3 or 4.
  • ring A is phenyl, T is CR1R2, W is CR4R5, V is CR3, Y is O, n is 3, and m is 3 or 4.
  • ring A is phenyl, p is 0, T is CR1R2, W is CR4R5, V is CR3, Y is O, n is 1, and m is 3 or 4.
  • ring A is phenyl, p is 0, T is CR1R2, W is CR4R5, V is CR3, Y is O, n is 2, and m is 3 or 4.
  • ring A is phenyl, p is 0, T is CR1R2, W is CR4R5, V is CR3, Y is O, n is 3, and m is 3 or 4.
  • p is 0 and Ri, R2, R4, and R5 are each H. In another embodiment of Formula (I), p is 0; Ri, R2, R4, and R5 are each H; and R3 is H. In another embodiment of Formula (I), p is 0; Ri, R2, R4, and R5 are each H; R3 is H; and R6, R7,
  • R8, R9, and R11 are each H.
  • p is 0; Ri, R2, R4, and R5 are each H; R3 is H; R6, R7, Rx. R9, and R11 are each H; and R12 and R13 are each H.
  • p is 1 and Ri, R2, R4, and R5 are each H. In another embodiment of Formula (I), p is 1; Ri, R2, R4, and Rs are each H; and R3 is H. In another embodiment of Formula (I), p is 1; Ri, R2, R4, and R5 are each H; R3 is H; and R6, R7,
  • R8, R9, and R11 are each H.
  • p is 1; Ri, R2, R4, and R5 are each H; R3 is H; R6, R7, Rs. R9, and R11 are each H; and R12 and R13 are each H.
  • p is 2 and Ri, R2, R4, and R5 are each H.
  • p is 2; Ri, R2, R4, and R5 are each H; and R3 is H.
  • p is 2; Ri, R2, R4, and R5 are each H; R3 is H; and R6, R7, R8, R9, and R11 are each H.
  • p is 2; Ri, R2, R4, and R5 are each H; R3 is H; and R6, R7, R8, R9, and R11 are each H.
  • p is 2; Ri, R2, R4, and R5 are each H; R3 is H; R6, R7, Rx. R9, and R11 are each H; and R12 and R13 are each H.
  • p is 1, 2, 3, or 4 and R is fluorine. In another embodiment of Formula (I), p is 1, 2, 3, or 4 and R is deuterium.
  • one or more of Ri, R2, R4, and R5 is fluorine. In another embodiment of Formula (I), one or more of Ri, R2, R4, and Rx is deuterium.
  • one or more of R6, R7, Rx. R9, and R11 is fluorine. In another embodiment of Formula (I), one or more of R6, R7, Rx. R9, and R11 is deuterium.
  • one or more of each R12 and R13 is fluorine. In another embodiment of Formula (I), one or more of each R12 and R13 is deuterium.
  • ring A is selected from the group consisting of phenyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, and triazinyl; n is 1, 2, or 3;
  • T is CR1R2 or O
  • W is CR4R5 or O
  • U is CR6R7
  • X is CR8R9
  • V is CR 3 orN
  • Y is NR10, O or absent
  • Z is (CRi 2 Ri3) m ;
  • R is halogen or deuterium; and p is 0, 1, 2, 3, or 4; and further wherein: m is 2, 3, 4, or 5 when Y is absent; or m is 1, 2, 3, or 4 when Y is NR10 or O;
  • Ri, R2, R4, and R5 are each, independently, selected from the group consisting of H, halogen, and deuterium; or, alternatively, R2 and R5 together with the carbon atoms to which they are attached, form a single bond;
  • R3 is selected from the group consisting of H, deuterium, halogen, hydroxyl, and cyano; or, alternatively, R3 and Ri, together with the carbon atoms to which they are attached, form a C3-C5 cycloalkyl; or, alternatively, R3 and R4, together with the carbon atoms to which they are attached, form a C3-C5 cycloalkyl;
  • R6, R7, Re, R9, and R11 are each, independently, selected from the group consisting of H, halogen, and deuterium;
  • Rio is selected from the group consisting of H, unsubstituted Ci-C3alkyl, and Ci- Cialkyl substituted with one or more halogen atoms; and each R12 and R13 is, independently, selected from the group consisting of H, halogen, deuterium, unsubstituted Ci-C3alkyl, and Ci-C3alkyl substituted with one or more halogen atoms.
  • ring A is selected from the group consisting of phenyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, and triazinyl; n is 1, 2, or 3;
  • T is CR1R2 or O
  • W is CR4R5 or O
  • U is CR6R7
  • X is CR8R9; V is CR3 or N;
  • Y is NR10, O or absent
  • Z is (CRi 2 Ri3) m ;
  • R is halogen or deuterium; and p is 0, 1, 2, 3, or 4; and further wherein: m is 2, 3, 4, or 5 when Y is absent; or m is 1, 2, 3, or 4 when Y is NR10 or O;
  • Ri, R2, R4, and R5 are each, independently, selected from the group consisting of H, halogen, and deuterium; or, alternatively, R2 and R5 together with the carbon atoms to which they are attached, form a single bond;
  • R3 is selected from the group consisting of H, deuterium, halogen, hydroxyl, and cyano; or, alternatively, R3 and Ri, together with the carbon atoms to which they are attached, form a C3-C5 cycloalkyl; or, alternatively, R3 and R4, together with the carbon atoms to which they are attached, form a C3-C5 cycloalkyl;
  • R6, R7, Re, R9, and R11 are each, independently, selected from the group consisting of H, halogen, and deuterium;
  • Rio is selected from the group consisting of H, unsubstituted Ci-C3alkyl, and Ci- C3alkyl substituted with one or more halogen atoms; and each R12 and R13 is, independently, selected from the group consisting of H, halogen, deuterium, unsubstituted Ci-C3alkyl, and Ci-C3alkyl substituted with one or more halogen atoms.
  • n is 1. In another embodiment of Formula (II), n is 2. In another embodiment of Formula (II), n is 3.
  • ring A is phenyl. In another embodiment of Formula (II), ring A is pyridinyl. In another embodiment of Formula (II), ring A is pyridazinyl. In another embodiment of Formula (II), ring A is pyrimidinyl. In another embodiment of Formula (II), ring A is pyrazinyl. In another embodiment of Formula (II), ring A is triazinyl.
  • Y is NR10. In another embodiment of Formula (II), Y is O. In another embodiment of Formula (II), Y is absent. In another embodiment of Formula (II), ring A is phenyl and Y is NR10. In another embodiment of Formula (II), ring A is phenyl and Y is O. In another embodiment of Formula (II), ring A is phenyl and Y is absent. In another embodiment of Formula (II), ring A is pyridinyl and Y is NR10. In another embodiment of Formula (II), ring A is pyridinyl and Y is O. In another embodiment of Formula (II), ring A is pyridinyl and Y is absent.
  • ring A is pyridazinyl and Y is NR10. In another embodiment of Formula (II), ring A is pyridazinyl and Y is O. In another embodiment of Formula (II), ring A is pyridazinyl and Y is absent. In another embodiment of Formula (II), ring A is pyrimidinyl and Y is NR10. In another embodiment of Formula (II), ring A is pyrimidinyl and Y is O. In another embodiment of Formula (II), ring A is pyrimidinyl and Y is absent. In another embodiment of Formula (II), ring A is pyrazinyl and Y is NR10.
  • ring A is pyrazinyl and Y is O. In another embodiment of Formula (II), ring A is pyrazinyl and Y is absent. In another embodiment of Formula (II), ring A is triazinyl and Y is NRio. In another embodiment of Formula (II), ring A is triazinyl and Y is O. In another embodiment of Formula (II), ring A is triazinyl and Y is absent.
  • T is CR1R2. In another embodiment of Formula (II), T is O. In another embodiment of Formula (II), W is CR4R5. In another embodiment of Formula (II), W is O. In another embodiment of Formula (II), T is CR1R2 and W is CR4R5. In another embodiment of Formula (II), T is O and W is CR4R5. In another embodiment of Formula (II), T is CR1R2 and W is O.
  • V is CR3. In another embodiment of Formula (II), V is N.
  • T is CR1R2 and V is CR3. In another embodiment of Formula (II), T is O and V is CR3. In another embodiment of Formula (II), T is CR1R2 and V is N. In another embodiment of Formula (II), T is O and V is N.
  • W is CR4R5 and V is CR3. In another embodiment of Formula (II), W is O and V is CR3. In another embodiment of Formula (II), W is CR4R5 and V is N. In another embodiment of Formula (II), W is O and V is N.
  • T is CR1R2, W is CR4R5, and V is CR3.
  • T is CR1R2, W is O, and V is CR3.
  • T is CR1R2, W is CR4R5, and V is N.
  • T is CR1R2, W is O, and V is N.
  • T is O, W is CR4R5, and V is CR3.
  • m is 1. In another embodiment of Formula (II), m is 2. In another embodiment of Formula (II), m is 3. In another embodiment of Formula (II), m is 4. In another embodiment of Formula (II), m is 5. In another embodiment of Formula (II), m is 1, 2 or 3. In another embodiment of Formula (II), m is 2, 3, or 4. In another embodiment of Formula (II), m is 1 or 2. In another embodiment of Formula (II), m is 3 or 4.
  • Y is O and m is 1. In another embodiment of Formula (II), Y is O and m is 2. In another embodiment of Formula (II), Y is O and m is 3.
  • Y is O and m is 4. In another embodiment of Formula (II), Y is O and m is 1, 2, or 3. In another embodiment of Formula (II), Y is O and m is 2, 3, or 4. In another embodiment of Formula (II), Y is O and m is 1 or 2. In another embodiment of Formula (II), Y is O and m is 3 or 4.
  • Y is absent and m is 1. In another embodiment of Formula (II), Y is absent and m is 2. In another embodiment of Formula (II), Y is absent and m is 3. In another embodiment of Formula (II), Y is absent and m is 4. In another embodiment of Formula (II), Y is absent and m is 1, 2, or 3. In another embodiment of Formula (II), Y is absent and m is 2, 3, or 4. In another embodiment of Formula (II), Y is absent and m is 1 or 2. In another embodiment of Formula (II), Y is absent and m is 3 or 4.
  • Y is NRio and m is 1. In another embodiment of Formula (II), Y is NRio and m is 2. In another embodiment of Formula (II), Y is NRio and m is 3. In another embodiment of Formula (II), Y is NRio and m is 4. In another embodiment of Formula (II), Y is NRio and m is 1, 2, or 3. In another embodiment of Formula (II), Y is NRio and m is 2, 3, or 4. In another embodiment of Formula (II), Y is NRio and m is 1 or 2. In another embodiment of Formula (II), Y is NRio and m is 3 or 4.
  • ring A is phenyl and n is 1. In another embodiment of Formula (II), ring A is phenyl and n is 2. In another embodiment of Formula (II), ring A is phenyl and n is 3. In another embodiment of Formula (II), ring A is pyridinyl and n is 1. In another embodiment of Formula (II), ring A is pyridinyl and n is 2. In another embodiment of Formula (II), ring A is pyridinyl and n is 3. In another embodiment of Formula (II), ring A is pyridazinyl and n is 1. In another embodiment of Formula (II), ring A is pyridazinyl and n is 2.
  • ring A is pyridazinyl and n is 3. In another embodiment of Formula (II), ring A is pyrimidinyl and n is 1. In another embodiment of Formula (II), ring A is pyrimidinyl and n is 2. In another embodiment of Formula (II), ring A is pyrimidinyl and n is 3. In another embodiment of Formula (II), ring A is pyrazinyl and n is 1. In another embodiment of Formula (II), ring A is pyrazinyl and n is 2. In another embodiment of Formula (II), ring A is pyrazinyl and n is 3.
  • ring A is triazinyl and n is 1. In another embodiment of Formula (II), ring A is triazinyl and n is 2. In another embodiment of Formula (II), ring A is triazinyl and n is 3.
  • ring A is phenyl, n is 1, and Y is NRio. In another embodiment of Formula (II), ring A is phenyl, n is 2, and Y is NRio. In another embodiment of Formula (II), ring A is phenyl, n is 3, and Y is NRio. In another embodiment of Formula (II), ring A is phenyl, n is 1, and Y is O. In another embodiment of Formula (II), ring A is phenyl, n is 2, and Y is O. In another embodiment of Formula (II), ring A is phenyl, n is 3, and Y is O.
  • ring A is phenyl, n is 1, and Y is absent. In another embodiment of Formula (II), ring A is phenyl, n is 2, and Y is absent. In another embodiment of Formula (II), ring A is phenyl, n is 3, and Y is absent. In another embodiment of Formula (II), ring A is phenyl, n is 1, Y is NRio, and m is 1 or 2. In another embodiment of Formula (II), ring A is phenyl, n is 2, Y is NRio, and m is 1 or 2.
  • ring A is phenyl, n is 3, Y is NRio, and m is 1 or 2. In another embodiment of Formula (II), ring A is phenyl, n is 1, Y is O, and m is 1 or 2.
  • ring A is phenyl, n is 2, Y is O, and m is 1 or 2. In another embodiment of Formula (II), ring A is phenyl, n is 3, Y is O, and m is 1 or 2. In another embodiment of Formula (II), ring A is phenyl, n is 1, Y is absent, and m is 1 or 2. In another embodiment of Formula (II), ring A is phenyl, n is 2, Y is absent, and m is 1 or 2. In another embodiment of Formula (II), ring A is phenyl, n is 3, Y is absent, and m is 1 or 2.
  • ring A is phenyl, n is 1, Y is NRio, and m is 3 or 4. In another embodiment of Formula (II), ring A is phenyl, n is 2, Y is NRio, and m is 3 or 4. In another embodiment of Formula (II), ring A is phenyl, n is 3, Y is NRio, and m is 3 or 4. In another embodiment of Formula (II), ring A is phenyl, n is 1, Y is O, and m is 3 or 4. In another embodiment of Formula (II), ring A is phenyl, n is 2, Y is O, and m is 3 or 4.
  • ring A is phenyl, n is 3, Y is O, and m is 3 or 4.
  • ring A is phenyl, n is 1, Y is absent, and m is 3 or 4.
  • ring A is phenyl, n is 2, Y is absent, and m is 3 or 4.
  • ring A is phenyl, n is 3, Y is absent, and m is 3 or 4.
  • ring A is pyridinyl, n is 1, and Y is NRio.
  • ring A is pyridinyl, n is 2, and Y is NRio.
  • ring A is pyridinyl, n is 3, and Y is NRio.
  • ring A is pyridinyl, n is 1, and Y is O.
  • ring A is pyridinyl, n is 2, and Y is O.
  • ring A is pyridinyl, n is 3, and Y is O.
  • ring A is pyridinyl, n is 1, and Y is absent. In another embodiment of Formula (II), ring A is pyridinyl, n is 2, and Y is absent. In another embodiment of Formula (II), ring A is pyridinyl, n is 3, and Y is absent.
  • ring A is pyridinyl, n is 1, Y is NRio, and m is 1 or 2. In another embodiment of Formula (II), ring A is pyridinyl, n is 2, Y is NRio, and m is 1 or 2. In another embodiment of Formula (II), ring A is pyridinyl, n is 3, Y is NRio, and m is 1 or 2. In another embodiment of Formula (II), ring A is pyridinyl, n is 1, Y is O, and m is 1 or 2. In another embodiment of Formula (II), ring A is pyridinyl, n is 2, Y is O, and m is 1 or 2.
  • ring A is pyridinyl, n is 3, Y is O, and m is 1 or 2.
  • ring A is pyridinyl, n is 1, Y is absent, and m is 1 or 2.
  • ring A is pyridinyl, n is 2, Y is absent, and m is 1 or 2.
  • ring A is pyridinyl, n is 3, Y is absent, and m is 1 or 2.
  • ring A is pyridinyl, n is 1, Y is NRio, and m is 3 or 4.
  • ring A is pyridinyl, n is 2, Y is NRio, and m is 3 or 4. In another embodiment of Formula (II), ring A is pyridinyl, n is 3, Y is NRio, and m is 3 or 4. In another embodiment of Formula (II), ring A is pyridinyl, n is 1,
  • Y is O, and m is 3 or 4.
  • ring A is pyridinyl, n is 2, Y is O, and m is 3 or 4.
  • ring A is pyridinyl, n is 3, Y is O, and m is 3 or 4.
  • ring A is pyridinyl, n is 1, Y is absent, and m is 3 or 4.
  • ring A is pyridinyl, n is 2, Y is absent, and m is 3 or 4.
  • ring A is pyridinyl, n is 3,
  • Y is absent, and m is 3 or 4.
  • ring A is pyridazinyl, n is 1, and Y is NRio.
  • ring A is pyridazinyl, n is 2, and Y is NRio. In another embodiment of Formula (II), ring A is pyridazinyl, n is 3, and Y is NRio. In another embodiment of Formula (II), ring A is pyridazinyl, n is 1, and Y is O. In another embodiment of Formula (II), ring A is pyridazinyl, n is 2, and Y is O. In another embodiment of Formula (II), ring A is pyridazinyl, n is 3, and Y is O.
  • ring A is pyridazinyl, n is 1, and Y is absent. In another embodiment of Formula (II), ring A is pyridazinyl, n is 2, and Y is absent. In another embodiment of Formula (II), ring A is pyridazinyl, n is 3, and Y is absent.
  • ring A is pyridazinyl, n is 1, Y is NRio, and m is 1 or 2. In another embodiment of Formula (II), ring A is pyridazinyl, n is 2, Y is NRio, and m is 1 or 2. In another embodiment of Formula (II), ring A is pyridazinyl, n is 3, Y is NRio, and m is 1 or 2. In another embodiment of Formula (II), ring A is pyridazinyl, n is 1, Y is O, and m is 1 or 2.
  • ring A is pyridazinyl, n is 2, Y is O, and m is 1 or 2. In another embodiment of Formula (II), ring A is pyridazinyl, n is 3, Y is O, and m is 1 or 2. In another embodiment of Formula (II), ring A is pyridazinyl, n is 1, Y is absent, and m is 1 or 2. In another embodiment of Formula (II), ring A is pyridazinyl, n is 2,
  • Y is absent, and m is 1 or 2.
  • ring A is pyridazinyl, n is 3, Y is absent, and m is 1 or 2.
  • ring A is pyridazinyl, n is 1, Y is NRio, and m is 3 or 4.
  • ring A is pyridazinyl, n is 2, Y is NRio, and m is 3 or 4.
  • ring A is pyridazinyl, n is 3, Y is NRio, and m is 3 or 4.
  • ring A is pyridazinyl, n is 1, Y is O, and m is 3 or 4.
  • ring A is pyridazinyl, n is 2, Y is O, and m is 3 or 4.
  • ring A is pyridazinyl, n is 3, Y is O, and m is 3 or 4.
  • ring A is pyridazinyl, n is 1, Y is absent, and m is 3 or 4.
  • ring A is pyridazinyl, n is 2, Y is absent, and m is 3 or 4.
  • ring A is pyridazinyl, n is 3, Y is absent, and m is 3 or 4.
  • ring A is pyrimidinyl, n is 1, and Y is NRio.
  • ring A is pyrimidinyl, n is 2, and Y is NRio. In another embodiment of Formula (II), ring A is pyrimidinyl, n is 3, and Y is NRio. In another embodiment of Formula (II), ring A is pyrimidinyl, n is 1, and Y is O. In another embodiment of Formula (II), ring A is pyrimidinyl, n is 2, and Y is O. In another embodiment of Formula (II), ring A is pyrimidinyl, n is 3, and Y is O. In another embodiment of Formula (II), ring A is pyrimidinyl, n is 1, and Y is absent. In another embodiment of Formula (II), ring A is pyrimidinyl, n is 2, and Y is absent. In another embodiment of Formula (II), ring A is pyrimidinyl, n is 3, and Y is absent.
  • ring A is pyrimidinyl, n is 1, Y is NRio, and m is 1 or 2. In another embodiment of Formula (II), ring A is pyrimidinyl, n is 2, Y is NRio, and m is 1 or 2. In another embodiment of Formula (II), ring A is pyrimidinyl, n is 3, Y is NRio, and m is 1 or 2. In another embodiment of Formula (II), ring A is pyrimidinyl, n is 1,
  • Y is O, and m is 1 or 2.
  • ring A is pyrimidinyl, n is 2,
  • Y is O, and m is 1 or 2.
  • ring A is pyrimidinyl, n is 3,
  • Y is O, and m is 1 or 2.
  • ring A is pyrimidinyl, n is 1,
  • Y is absent, and m is 1 or 2.
  • ring A is pyrimidinyl, n is 2, Y is absent, and m is 1 or 2.
  • ring A is pyrimidinyl, n is 3, Y is absent, and m is 1 or 2.
  • ring A is pyrimidinyl, n is 1, Y is NRio, and m is 3 or 4.
  • ring A is pyrimidinyl, n is 2, Y is NRio, and m is 3 or 4.
  • ring A is pyrimidinyl, n is 3, Y is NRio, and m is 3 or 4.
  • ring A is pyrimidinyl, n is 1, Y is O, and m is 3 or 4.
  • ring A is pyrimidinyl, n is 1, Y is O, and m is 3 or 4.
  • ring A is pyrimidinyl, n is 2, Y is O, and m is 3 or 4.
  • ring A is pyrimidinyl, n is 3, Y is O, and m is 3 or 4.
  • ring A is pyrimidinyl, n is 1, Y is absent, and m is 3 or 4. In another embodiment of Formula (II), ring A is pyrimidinyl, n is 2, Y is absent, and m is 3 or 4. In another embodiment of Formula (II), ring A is pyrimidinyl, n is 3, Y is absent, and m is 3 or 4.
  • ring A is pyrazinyl, n is 1, and Y is NRio.
  • ring A is pyrazinyl, n is 2, and Y is NRio.
  • ring A is pyrazinyl, n is 3, and Y is NRio.
  • ring A is pyrazinyl, n is 1, and Y is O.
  • ring A is pyrazinyl, n is 2, and Y is O.
  • ring A is pyrazinyl, n is 3, and Y is O.
  • ring A is pyrazinyl, n is 1, and Y is absent. In another embodiment of Formula (II), ring A is pyrazinyl, n is 2, and Y is absent. In another embodiment of Formula (II), ring A is pyrazinyl, n is 3, and Y is absent.
  • ring A is pyrazinyl, n is 1, Y is NRio, and m is 1 or 2. In another embodiment of Formula (II), ring A is pyrazinyl, n is 2, Y is NRio, and m is 1 or 2. In another embodiment of Formula (II), ring A is pyrazinyl, n is 3, Y is NRio, and m is 1 or 2. In another embodiment of Formula (II), ring A is pyrazinyl, n is 1, Y is O, and m is 1 or 2. In another embodiment of Formula (II), ring A is pyrazinyl, n is 2, Y is O, and m is 1 or 2.
  • ring A is pyrazinyl, n is 3, Y is O, and m is 1 or 2.
  • ring A is pyrazinyl, n is 1, Y is absent, and m is 1 or 2.
  • ring A is pyrazinyl, n is 2, Y is absent, and m is 1 or 2.
  • ring A is pyrazinyl, n is 3, Y is absent, and m is 1 or 2.
  • ring A is pyrazinyl, n is 1, Y is NRio, and m is 3 or 4.
  • ring A is pyrazinyl, n is 2, Y is NRio, and m is 3 or 4. In another embodiment of Formula (II), ring A is pyrazinyl, n is 3, Y is NRio, and m is 3 or 4. In another embodiment of Formula (II), ring A is pyrazinyl, n is 1, Y is O, and m is 3 or 4. In another embodiment of Formula (II), ring A is pyrazinyl, n is 2, Y is O, and m is 3 or 4. In another embodiment of Formula (II), ring A is pyrazinyl, n is 3, Y is O, and m is 3 or 4.
  • ring A is pyrazinyl, n is 1, Y is absent, and m is 3 or 4. In another embodiment of Formula (II), ring A is pyrazinyl, n is 2, Y is absent, and m is 3 or 4. In another embodiment of Formula (II), ring A is pyrazinyl, n is 3, Y is absent, and m is 3 or 4.
  • ring A is triazinyl, n is 1, and Y is NRio. In another embodiment of Formula (II), ring A is triazinyl, n is 2, and Y is NRio. In another embodiment of Formula (II), ring A is triazinyl, n is 3, and Y is NRio. In another embodiment of Formula (II), ring A is triazinyl, n is 1, and Y is O. In another embodiment of Formula (II), ring A is triazinyl, n is 2, and Y is O. In another embodiment of Formula (II), ring A is triazinyl, n is 3, and Y is O.
  • ring A is triazinyl, n is 1, and Y is absent. In another embodiment of Formula (II), ring A is triazinyl, n is 2, and Y is absent. In another embodiment of Formula (II), ring A is triazinyl, n is 3, and Y is absent.
  • ring A is triazinyl, n is 1, Y is NRio, and m is
  • ring A is triazinyl, n is 2, Y is NRio, and m is
  • ring A is triazinyl, n is 3, Y is NRio, and m is
  • ring A is triazinyl, n is 1, Y is O, and m is 1 or 2. In another embodiment of Formula (II), ring A is triazinyl, n is 2, Y is O, and m is 1 or 2. In another embodiment of Formula (II), ring A is triazinyl, n is 3, Y is O, and m is 1 or 2. In another embodiment of Formula (II), ring A is triazinyl, n is 1, Y is absent, and m is 1 or 2. In another embodiment of Formula (II), ring A is triazinyl, n is 2, Y is absent, and m is 1 or 2.
  • ring A is triazinyl, n is 3, Y is absent, and m is 1 or 2.
  • ring A is triazinyl, n is 1, Y is NRio, and m is 3 or 4.
  • ring A is triazinyl, n is 2, Y is NRio, and m is 3 or 4.
  • ring A is triazinyl, n is 3, Y is NRio, and m is 3 or 4.
  • ring A is triazinyl, n is 1, Y is O, and m is 3 or 4.
  • ring A is triazinyl, n is 2, Y is O, and m is 3 or 4. In another embodiment of Formula (II), ring A is triazinyl, n is 3, Y is O, and m is 3 or 4. In another embodiment of Formula (II), ring A is triazinyl, n is 1, Y is absent, and m is 3 or 4.
  • ring A is triazinyl, n is 2, Y is absent, and m is 3 or 4. In another embodiment of Formula (II), ring A is triazinyl, n is 3, Y is absent, and m is 3 or 4.
  • ring A is phenyl, T is CR1R2, W is CR4R5, and V is CR3.
  • ring A is phenyl, p is 0, T is CR1R2,
  • W is CR4R5, and V is CR3.
  • ring A is phenyl, T is CR1R2, W is CR4R5, V is CR3, and n is 1.
  • ring A is phenyl, T is CR1R2, W is CR4R5, V is CR3, and n is 2.
  • ring A is phenyl, T is CR1R2, W is CR4R5, V is CR3, and n is 3.
  • ring A is phenyl, p is 0, T is CR1R2, W is CR4R5, V is CR3, and n is 1.
  • ring A is phenyl, p is 0, T is CR1R2, W is CR4R5, V is CR3, and n is 2.
  • ring A is phenyl, p is 0, T is CR1R2, W is CR4R5, V is CR3, and n is 3.
  • ring A is phenyl, T is CR1R2, W is CR4R5, V is CR3, and Y is O.
  • ring A is phenyl, p is 0, T is CR1R2, W is CR4R5, V is CR3, and Y is O.
  • ring A is phenyl, T is CR1R2, W is CR4R5, V is CR3, Y is O, and n is 1.
  • ring A is phenyl, T is CR1R2, W is CR4R5, V is CR3, Y is O, and n is 2.
  • ring A is phenyl, T is CR1R2, W is CR4R5, V is CR3, Y is O, and n is 3.
  • ring A is phenyl, p is 0, T is CR1R2, W is CR4R5, V is CR3, Y is O, and n is 1.
  • ring A is phenyl, p is 0, T is CR1R2, W is CR4R5, V is CR3, Y is O, and n is 2.
  • ring A is phenyl, p is 0, T is CR1R2, W is CR4R5, V is CR3, Y is O, and n is 3.
  • ring A is phenyl, T is CR1R2, W is CR4R5, V is CR3, Y is O, and m is 1 or 2.
  • ring A is phenyl, p is 0, T is CR1R2, W is CR4R5, V is CR3, Y is O, and m is 1 or 2.
  • ring A is phenyl, T is CR1R2, W is CR4R5, V is CR3, Y is O, n is 1, and m is 1 or 2.
  • ring A is phenyl, T is CR1R2, W is CR4R5, V is CR3, Y is O, n is 2, and m is 1 or 2.
  • ring A is phenyl, T is CR1R2, W is CR4R5, V is CR3, Y is O, n is 3, and m is 1 or 2.
  • ring A is phenyl, p is 0, T is CR1R2, W is CR4R5, V is CR3, Y is O, n is 1, and m is 1 or 2.
  • ring A is phenyl, p is 0, T is CR1R2, W is CR4R5, V is CR3, Y is O, n is 2, and m is 1 or 2.
  • ring A is phenyl, p is 0, T is CR1R2, W is CR4R5, V is CR3, Y is O, n is 3, and m is 1 or 2.
  • ring A is phenyl, T is CR1R2, W is CR4R5, V is CR3, Y is O, and m is 3 or 4.
  • ring A is phenyl, p is 0, T is CR1R2, W is CR4R5, V is CR3, Y is O, and m is 3 or 4.
  • ring A is phenyl, T is CR1R2, W is CR4R5, V is CR3, Y is O, n is 1, and m is 3 or 4.
  • ring A is phenyl, T is CR1R2, W is CR4R5, V is CR3, Y is O, n is 2, and m is 3 or 4.
  • ring A is phenyl, T is CR1R2, W is CR4R5, V is CR3, Y is O, n is 3, and m is 3 or 4.
  • ring A is phenyl, p is 0, T is CR1R2, W is CR4R5, V is CR3, Y is O, n is 1, and m is 3 or 4.
  • ring A is phenyl, p is 0, T is CR1R2, W is CR4R5, V is CR3, Y is O, n is 2, and m is 3 or 4.
  • ring A is phenyl, p is 0, T is CR1R2, W is CR4R5, V is CR3, Y is O, n is 3, and m is 3 or 4.
  • p is 0 and Ri, R2, R4, and R5 are each H.
  • p is 0; Ri, R2, R4, and R5 are each H; and R3 is H.
  • p is 0; Ri, R2, R4, and R5 are each H; R3 is H; and R6,
  • R7, R8, R9, and R11 are each H.
  • p is 0; Ri, R2, R4, and R5 are each H; R3 is H; R6, R7, Rs, R9, and R11 are each H; and R12 and R13 are each H.
  • p is 1 and Ri, R2, R4, and R5 are each H. In another embodiment of Formula (II), p is 1; Ri, R2, R4, and R5 are each H; and R3 is H. In another embodiment of Formula (II), p is 1; Ri, R2, R4, and R5 are each H; R3 is H; and R6,
  • R7, Rs, R9, and R11 are each H.
  • p is 1; Ri, R2, R4, and R5 are each H; R3 is H; R6, R7, Rs, R9, and R11 are each H; and R12 and R13 are each H.
  • p is 2 and Ri, R2, R4, and R5 are each H. In another embodiment of Formula (II), p is 2; Ri, R2, R4, and R5 are each H; and R3 is H. In another embodiment of Formula (II), p is 2; Ri, R2, R4, and R5 are each H; R3 is H; and R6,
  • R7, Rs, R9, and R11 are each H.
  • p is 2; Ri, R2, R4, and R5 are each H; R3 is H; R6, R7, Rs, R9, and R11 are each H; and R12 and R13 are each H.
  • p is 1, 2, 3, or 4 and R is fluorine. In another embodiment of Formula (II), p is 1, 2, 3, or 4 and R is deuterium.
  • one or more of Ri, R2, R4, and R5 is fluorine. In another embodiment of Formula (II), one or more of Ri, R2, R4, and R5 is deuterium.
  • one or more of R6, R7, Rs, R9, and R11 is fluorine. In another embodiment of Formula (II), one or more of R6, R7, Rs, R9, and R11 is deuterium.
  • one or more of each R12 and R13 is fluorine. In another embodiment of Formula (II), one or more of each R12 and R13 is deuterium.
  • compounds described herein are present in optically active or racemic forms. It is to be understood that the compounds described herein encompass racemic, optically-active, regioisomeric and stereoisomeric forms, or combinations thereof that possess the therapeutically useful properties described herein.
  • Preparation of optically active forms is achieved in any suitable manner, including by way of non-limiting example, by resolution of the racemic form with recrystallization techniques, synthesis from optically-active starting materials, chiral synthesis, or chromatographic separation using a chiral stationary phase.
  • a mixture of two or more isomers is utilized as the disclosed compound described herein.
  • a pure isomer is utilized as the disclosed compound described herein.
  • compounds described herein contain one or more chiral centers. These compounds are prepared by any means, including stereoselective synthesis, enantioselective synthesis or separation of a mixture of enantiomers or diastereomers.
  • Compounds described herein also include isotopically-labeled compounds wherein one or more atoms is replaced by an atom having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number usually found in nature.
  • isotopes suitable for inclusion in the compounds described herein include and are not limited to 2 H, 3 H, n C, 13 C, 14 C, 36 C1, 18 F, 123 I, 125 I, 13 N, 15 N, 15 0, 17 0, 18 0, 32 P, and 35 S.
  • isotopically-labeled compounds are useful in drug or substrate tissue distribution studies.
  • substitution with heavier isotopes such as deuterium affords greater metabolic stability (for example, increased in vivo half-life or reduced dosage requirements).
  • the compounds described herein include a 2 H (i.e., deuterium) isotope.
  • substitution with positron emitting isotopes is useful in Positron Emission Topography (PET) studies for examining substrate receptor occupancy.
  • Isotopically-labeled compounds are prepared by any suitable method or by processes using an appropriate isotopically-labeled reagent in place of the non- labeled reagent otherwise employed.
  • the compounds of the invention can be used in a method of treating a disease or condition in a subject, said method comprising administering to the subject a compound of the invention, or a pharmaceutical composition comprising a compound of the invention.
  • the subject is human.
  • the compounds provided herein are useful in treatment of a disease or condition by acting as an agonist of the orexin-2 receptor.
  • the compounds of the invention can be used to treat a disease or condition selected from the group consisting of narcolepsy, cataplexy, or hypersomnia in a subject in need thereof.
  • the compounds of the invention can be used to treat narcolepsy in a subject. In one embodiment, the compounds of the invention can be used to treat cataplexy in a subject. In one embodiment, the compounds of the invention can be used to treat hypersomnia in a subject.
  • Orexin-2 receptors are important in a wide range of biological functions. This suggests that orexin-2 receptors play a role in diverse disease processes in humans or other species.
  • the compound of the present invention is useful for treating, preventing, or ameliorating the risk of one or more of the following symptoms or diseases of various neurological and psychiatric diseases associated with alterations in sleep/wake function.
  • narcolepsy narcolepsy with cataplexy, idiopathic hypersomnia, hypersomnia, sleep apnea syndrome, narcolepsy syndrome, hypersomnolence syndrome characterized by hypersomnia (e.g., in subjects with Kleine Levin syndrome, major depression with hypersomnia, Lewy body dementia, Parkinson’s disease, progressive supranuclear paralysis, Prader-Willi syndrome, Mobius syndrome, hypoventilation syndrome, Niemann-Pick disease type C, brain contusion, cerebral infarction, brain tumor, muscular dystrophy, multiple sclerosis, multiple systems atrophy, acute disseminated encephalomyelitis, Guillain-Barre syndrome, Rasmussen’s encephalitis, Wernicke’s encephalitis, limbic encephalitis, or Hashimoto’s encephalopathy), coma, loss of consciousness, obesity (e.g., malignant mastocytosis, exogenous obesity
  • the compound of the present invention is useful as a therapeutic or prophylactic drug for narcolepsy, idiopathic hypersomnia, hypersomnia, sleep apnea syndrome, narcolepsy syndrome, hypersomnolence syndrome characterized by hypersomnia (e.g., in Parkinson’s disease, Guillain-Barre syndrome or Kleine Levin syndrome), Alzheimer’s disease, obesity, insulin resistance syndrome, cardiac failure, diseases related to bone loss, sepsis, disturbance of consciousness such as coma and the like, side effects and complications due to anesthesia, and the like, or anesthetic antagonist.
  • hypersomnia e.g., in Parkinson’s disease, Guillain-Barre syndrome or Kleine Levin syndrome
  • Alzheimer’s disease e.g., in Parkinson’s disease, Guillain-Barre syndrome or Kleine Levin syndrome
  • Alzheimer’s disease e.g., in Parkinson’s disease, Guillain-Barre syndrome or Kleine Levin syndrome
  • the compound of the present invention has orexin-2 receptor agonist activity and is useful as a prophylactic or therapeutic agent for narcolepsy.
  • the compound of the present invention is useful as a prophylactic or therapeutic agent for narcolepsy type-1. In another embodiment, the compound of the present invention is useful as a prophylactic or therapeutic agent for narcolepsy type-2. In another embodiment, the compound of the present invention is useful as a prophylactic or therapeutic agent for narcolepsy and excessive daytime sleepiness. In another embodiment, the compound of the present invention is useful as a prophylactic or therapeutic agent for narcolepsy, cataplexy, and excessive daytime sleepiness. In another embodiment, the compound of the present invention is useful as a prophylactic or therapeutic agent for narcolepsy and cataplexy.
  • the compound of the present invention is useful as a prophylactic or therapeutic agent for excessive daytime sleepiness. In another embodiment, the compound of the present invention is useful as a prophylactic or therapeutic agent for idiopathic hypersomnia. In another embodiment, the compound of the present invention is useful as a prophylactic or therapeutic agent for obstructive sleep apnea. In another embodiment, the compound of the present invention has orexin-2 receptor agonist activity and is useful as a prophylactic or therapeutic agent for hypersomnia in Parkinson’s disease.
  • the compound of the present invention has orexin-2 receptor agonist activity and is useful as a prophylactic or therapeutic agent for hypersomnia. In another embodiment, the compound of the present invention has orexin-2 receptor agonist activity and is useful as a prophylactic or therapeutic agent for excessive daytime sleepiness associated with Parkinson's disease.
  • the compound of the present invention has orexin-2 receptor agonist activity and is useful as a prophylactic or therapeutic agent for excessive daytime sleepiness or fatigue associated with cancer and/or chemotherapy.
  • the present invention provides a method of treating narcolepsy in a subject in need thereof comprising administering to the subject a compound of Formula I-A, I, II- A, or II, or a pharmaceutically acceptable salt thereof.
  • the present invention provides a method of treating narcolepsy type-1 in a subject in need thereof comprising administering to the subject a compound of Formula I-A, I, II-A, or II, or a pharmaceutically acceptable salt thereof.
  • the present invention provides a method of treating narcolepsy type-2 in a subject in need thereof comprising administering to the subject a compound of Formula I-A, I, II-A, or II, or a pharmaceutically acceptable salt thereof.
  • the present invention provides a method of treating narcolepsy and excessive daytime sleepiness in a subject in need thereof comprising administering to the subject a compound of Formula I-A, I, II-A, or II, or a pharmaceutically acceptable salt thereof.
  • the present invention provides a method of treating narcolepsy, cataplexy, and excessive daytime sleepiness in a subject in need thereof comprising administering to the subject a compound of Formula I-A, I, II-A, or II, or a pharmaceutically acceptable salt thereof.
  • the present invention provides a method of treating narcolepsy and cataplexy in a subject in need thereof comprising administering to the subject a compound of Formula I-A, I, II-A, or II, or a pharmaceutically acceptable salt thereof.
  • the present invention provides a method of treating excessive daytime sleepiness in a subject in need thereof comprising administering to the subject a compound of Formula I-A, I, II-A, or II, or a pharmaceutically acceptable salt thereof.
  • the present invention provides a method of treating idiopathic hypersomnia in a subject in need thereof comprising administering to the subject a compound of Formula I-A, I, II- A, or II, or a pharmaceutically acceptable salt thereof.
  • the present invention provides a method of treating excessive daytime sleepiness and idiopathic hypersomnia in a subject in need thereof comprising administering to the subject a compound of Formula I-A, I, II-A, or II, or a pharmaceutically acceptable salt thereof.
  • the present invention provides a method of treating obstructive sleep apnea in a subject in need thereof comprising administering to the subject a compound of Formula I-A, I, II-A, or II, or a pharmaceutically acceptable salt thereof.
  • the present invention provides a method of treating excessive daytime sleepiness and obstructive sleep apnea in a subject in need thereof comprising administering to the subject a compound of Formula I-A, I, II-A, or II, or a pharmaceutically acceptable salt thereof.
  • the subject is administered a compound of Formula I. In any of the methods as described herein, the subject is administered a compound of Formula II.
  • the compound of Formula I-A, I, II-A, II, or a pharmaceutically acceptable salt thereof is present and/or administered in a therapeutically effective amount.
  • composition comprising at least one compound of the invention, together with a pharmaceutically acceptable carrier.
  • Actual dosage levels of the active ingredients in the pharmaceutical compositions of this invention may be varied so as to obtain an amount of the active ingredient that is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.
  • the selected dosage level will depend upon a variety of factors including the activity of the particular compound employed, the time of administration, the rate of excretion of the compound, the duration of the treatment, other drugs, compounds or materials used in combination with the compound, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well, known in the medical arts.
  • a medical doctor e.g., physician or veterinarian, having ordinary skill in the art may readily determine and prescribe the effective amount of the pharmaceutical composition required.
  • physician or veterinarian could begin administration of the pharmaceutical composition to dose the disclosed compound at levels lower than that required in order to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved.
  • Dosage unit form refers to physically discrete units suited as unitary dosages for the patients to be treated; each unit containing a predetermined quantity of the disclosed compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical vehicle.
  • the dosage unit forms of the invention are dictated by and directly dependent on (a) the unique characteristics of the disclosed compound and the particular therapeutic effect to be achieved, and (b) the limitations inherent in the art of compounding/formulating such a disclosed compound for the treatment of narcolepsy or cataplexy in a patient.
  • the compounds of the invention are formulated using one or more pharmaceutically acceptable excipients or carriers.
  • the pharmaceutical compositions of the invention comprise a therapeutically effective amount of a disclosed compound and a pharmaceutically acceptable carrier.
  • the dose of a disclosed compound is from about 1 mg to about 1,000 mg. In some embodiments, a dose of a disclosed compound used in compositions described herein is less than about 1,000 mg, or less than about 800 mg, or less than about 600 mg, or less than about 500 mg, or less than about 300 mg, or less than about 200 mg, or less than about 100 mg, or less than about 50 mg, or less than about 20 mg, or less than about 10 mg.
  • a dose is about 10 mg, 20 mg, 25 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 80 mg, 90 mg, 100 mg, 120 mg, 140 mg, 160 mg, 180 mg, 200 mg, 220 mg, 240, 260 mg, 280 mg, 300 mg, 350 mg, 400 mg, 450 mg, 500 mg, 550 mg, or about 600 mg.
  • Routes of administration of any of the compositions of the invention include oral, nasal, rectal, intravaginal, parenteral, buccal, sublingual or topical.
  • the compounds for use in the invention may be formulated for administration by any suitable route, such as for oral or parenteral, for example, transdermal, transmucosal (e.g., sublingual, lingual, (trans)buccal, (trans)urethral, vaginal (e.g., trans- and perivaginally), (intra)nasal and (trans)rectal), intravesical, intrapulmonary, intraduodenal, intragastrical, intrathecal, subcutaneous, intramuscular, intradermal, intra-arterial, intravenous, intrabronchial, inhalation, and topical administration.
  • the preferred route of administration is oral.
  • compositions and dosage forms include, for example, tablets, capsules, caplets, pills, gel caps, troches, dispersions, suspensions, solutions, syrups, granules, beads, transdermal patches, gels, powders, pellets, magmas, lozenges, creams, pastes, plasters, lotions, discs, suppositories, liquid sprays for nasal or oral administration, dry powder or aerosolized formulations for inhalation, compositions and formulations for intravesical administration and the like. It should be understood that the formulations and compositions that would be useful in the present invention are not limited to the particular formulations and compositions that are described herein.
  • compositions intended for oral use may be prepared according to any method known in the art and such compositions may contain one or more agents selected from the group consisting of inert, non-toxic pharmaceutically excipients that are suitable for the manufacture of tablets.
  • excipients include, for example an inert diluent such as lactose; granulating and disintegrating agents such as cornstarch; binding agents such as starch; and lubricating agents such as magnesium stearate.
  • the tablets may be uncoated or they may be coated by known techniques for elegance or to delay the release of the active ingredients.
  • Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert diluent.
  • the disclosed compounds may be formulated for injection or infusion, for example, intravenous, intramuscular or subcutaneous injection or infusion, or for administration in a bolus dose or continuous infusion.
  • Suspensions, solutions or emulsions in an oily or aqueous vehicle, optionally containing other formulatory agents such as suspending, stabilizing or dispersing agents may be used.
  • reaction conditions including but not limited to reaction times, reaction size/volume, and experimental reagents, such as solvents, catalysts, pressures, atmospheric conditions, e.g., nitrogen atmosphere, and reducing/oxidizing agents, are within the scope of the present application.
  • HATU 1 -
  • DIPEA XX-di isopropyl ethyl amine
  • PE petroleum ether
  • EtOAc ethyl acetate
  • DMF dimethyl formamide
  • TFA trifluoroacetic acid
  • EA ethyl acetate
  • LiOFEFhO lithium hydroxide monohydrate
  • TMSOTf trimethylsilyl trifluoromethanesulfonate
  • DIAD diisopropyl azodicarboxylate
  • XantPhos 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene
  • TBS /e/V-butyldimethylsilyl
  • KHMDS Potassium bis(trimethylsilyl)amide solution
  • Bfbl toS borane dimethyl sulfide complex
  • TMSC1 chlorotrimethylsilane
  • DMPU l,3-dimethyl-3,4,5,6-tetrahydro-2(lH)-pyrimidinone
  • LDA lithium diisopropylamide
  • DBU l,8-diazabicyclo[5.4.0]undec-7-ene
  • CMPI 2-chloro-l-methylpyridinium iodide
  • IrCl(CO)(PPh 3 )2 bis(triphenylphosphine)iridium(I) carbonyl chloride
  • racemic product was purified by Chiral-HPLC to provide 50 mg (41.60%) of N-((2 1 S,2*S,5 2 R,5 3 S)-6- oxo-3, 11 -dioxa-5(2, 1 )-piperidina-l (1 ,2)-benzena-2(l ,4)-cy clohexanacycloundecaphane-5 3 - yl)methanesulfonamide as a solid.
  • the resulting mixture was diluted with water (20 mL). The resulting mixture was extracted with EtOAc (2 x 10 mL). The combined organic layers were washed with brine (10 mL), dried over anhydrous Na2SC>4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE/EtOAc (3:1). The resulting mixture was concentrated under vacuum.
  • Ethyl bromoacetate (279 mg, 1.671 mmol, 1.5 equiv.) was added dropwise into a mixture of /er/-butyl N- ⁇ 2-(
  • Example 1.19 (Compound 59) To a stirred solution of/V-((2 1 S,2 4 S,5 2 R,5 3 S)-l 3 ,l 5 ,7,7-tetrafluoro-6-oxo-3,8-dioxa- 5(2, l)-piperidina-l (1 ,2)-benzena-2(l ,4)-cyclohexanacyclooctaphane-5 3 -yl) methanesulfonam ide (12.0 mg, 1.0 equiv., 0.024 mmol) in THF (2.0 mL) was added BH3Me2S (18.4 mg, 10.0 equiv., 0.24 mmol) dropwise at 0 degrees C under nitrogen atmosphere.
  • MeMgBr (85.0 mg, 3.0 equiv., 0.711 mmol) was added into the mixture at -78 degrees C under nitrogen atmosphere. The resulting mixture was stirred for 4 hr at room temperature under nitrogen atmosphere.
  • T-Rex CHO cells stably overexpressing the human orexin-2 receptor (OX2R) were induced overnight with 1 pg/mL of doxycycline in a T225 flask. 24 hours post induction, cells were lifted with accutase and plated into a 384-well proxy plate at 30,000 cells/well. Cells were then treated with different test compounds in IX stimulation buffer containing 10 mM Hepes, 1 mM CaCh, 0.5 mM MgCh, 4.2 mM KC1, 146 mM NaCl, 5.5 mM glucose, and 50 mM LiCl, pH 7.4, for 1 hr at 37 degrees C.
  • IX stimulation buffer containing 10 mM Hepes, 1 mM CaCh, 0.5 mM MgCh, 4.2 mM KC1, 146 mM NaCl, 5.5 mM glucose, and 50 mM LiCl, pH 7.4, for 1 hr at 37 degrees C.
  • detection mix which is composed of IPl-d2 and anti-IPl- cryptate diluted in lysis buffer as well as IX stimulation buffer.
  • detection mix which is composed of IPl-d2 and anti-IPl- cryptate diluted in lysis buffer as well as IX stimulation buffer.
  • the plates were allowed to incubate for 1 hour at room temperature and were then read in the EnVision® multimode plate reader, measuring inositol phosphate levels.
  • Cisbio IP 1 is a cell-based functional assay quantifying the accumulation of inositol monophosphate (IP), a metabolite released as a result of orexin 2 receptor activation through the phospholipase C-Gq signaling pathway.
  • IP inositol monophosphate
  • This is a competitive immunoassay in which the IP1 produced by the cells upon receptor activation competes with the IP1 analog coupled to the d2 fluorophore (acceptor) for binding to an anti-IP 1 monoclonal antibody labeled with Eu cryptate (donor).
  • the measured HTRF-FRET based signal is inversely proportional to the IP1 concentration produced.
  • the EC50 values reported in Table 2 were obtained according to the human OX2R IP1 assay described above. Data are the mean EC50 values ⁇ S.E.M.
  • the compound methyl ( 2/i.3.Y)-3-((methylsul ronyl)amino)-2-(((67.v -4-phenylcy cl ohexyl)oxy (methyl (-piperidine- 1 - carboxylate is a reference compound which is disclosed in Example 5 of PCT publication no. WO2017/135306.
  • the bidirectional permeability (Apical to Basal and Basal to Apical directions) of test compounds in MDCK-MDR1 cells were evaluated using MDCK-MDR1 cells seeded in Solvo PreadyPortTM MDCK 96-well plate. Once the plate was received from ReadyCell (Barcelona, Spain), it was treated as per PreadyPortTM user’s manual.
  • test compound (3 pM) co-dosed with LY (Lucifer Yellow) (100 pM) in HBSS (Hank’s Balanced Salt Solution) assay buffer was added to the donor side (A) while 250 pL of HBSS buffer was added to the receiver side (B).
  • HBSS Hank’s Balanced Salt Solution
  • 255 pL of test compound (3 pM) in HBSS assay buffer was added to the donor side (B) while 75 pL of HBSS buffer containing LY (100 pM) was added to the receiver side (A).
  • the plate was placed in an incubator set at 37 degrees C. After 10 minutes of pre warming, 5 pL aliquot was taken from donor compartment and set aside as the dosing solution.
  • the MDCK-MDR1 incubation plate was placed back into the incubator for 2 hours of incubation at 37 degrees C. After 2 hours of incubation, 25 pL and 5 pL aliquots were removed from the receiver and donor sides, respectively.
  • To the 5 pL aliquots taken from the donor sides (before and after a 2-hour incubation) were diluted with 20 pL of the HBSS buffer. All samples were mixed with 150 pL with acetonitrile containing internal standard (IS) and 200 pL water, and analyzed by LC-MS/MS.
  • IS acetonitrile containing internal standard
  • Co initial concentration of product applied in apical (A B) or basal (B A) compartment (nmol/mL)
  • the efflux ratio (ER) was measured by dividing the Papp (basolateral to apical direction) by Papp (apical to basolateral direction). It is a general measure of the involvement of active processes. An ER > 2 is considered positive for active transport.
  • VD Volume of the donor compartment (mL)
  • cryopreserved hepatocytes from male Sprague Dawley rats and a pool of 50 mixed gender humans (BioIVT, Baltimore, MD).
  • the incubation mixtures were prepared by mixing 250 pL of pre-warmed KHB (Krebs-Henseleit buffer) containing 2 c 10 6 cell/mL of hepatocytes with 250 pL of pre-warmed KHB buffer containing 2 pM of test compounds in a 48-well plate, giving a final concentration of 1 pM test compound (0.1% DMSO) and 1 x 10 6 cell/mL of hepatocytes.
  • the reaction mixture was incubated at 37 degrees C.
  • a 50 pL aliquot of incubation mixture was taken at time points (0, 15, 30, 60, 120 and 240 minutes) and transferred into a 96-well plate containing 300 pL ice-cold acetonitrile (containing 30 ng/mL of labetalol and 10 ng/mL ofNaltrexone-d3 as internal standards) and immediately placed in ice to terminate the reaction. Samples were centrifuged, and supernatants were transferred into 96-well plates for liquid chromatography with tandem mass spectrometry (LC-MS/MS) analysis to monitor the depletion of the test compound.
  • LC-MS/MS tandem mass spectrometry
  • the in vitro T1/2 was converted to in vitro intrinsic clearance (CLint, hep) in units of mL/min/kg using the formula shown below:
  • the extraction ratio (ER) was calculated by dividing the hepatic clearance of a compound to the liver blood flow.
  • the data reported in Table 5 were obtained according to the human hepatocytes stability assay described above. Table 5
  • EEG and EMG data were recorded using the DSI telemetry system and Ponemah software (Data Sciences International Inc., MN, USA). Sleep-wake stages were scored both manually and with Somnivore, a supervised machine learning software platform, in 10 second epocs. Records were visually inspected as needed post-processing.
  • Wakefulness time is derived from the sleep-wake stage analysis.
  • Cortical activation time is based on the duration in which frontal gamma oscillatory activity (30-100Hz), a key feature of wakefulness, was elevated relative to a pre-treatment baseline.
  • Mean cortical activation time was computed relative to vehicle treatment for the 6-hour post-dose period. Results are shown in Table 6 below. Table 6
  • PO oral
  • SC subcutaneous
  • mpk milligram per kilogram

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
PCT/US2020/062320 2019-11-25 2020-11-25 Substituted macrocyclic compounds and related methods of treatment Ceased WO2021108628A1 (en)

Priority Applications (26)

Application Number Priority Date Filing Date Title
RS20250911A RS67202B1 (sr) 2019-11-25 2020-11-25 Supstituisana makrociklična jedinjenja i srodni postupci lečenja
CN202080081320.8A CN114761412B (zh) 2019-11-25 2020-11-25 取代的大环化合物和相关治疗方法
EP25195771.8A EP4628167A3 (en) 2019-11-25 2020-11-25 Substituted macrocyclic compounds and related methods of treatment
AU2020394444A AU2020394444B2 (en) 2019-11-25 2020-11-25 Substituted macrocyclic compounds and related methods of treatment
DK20828463.8T DK4065585T3 (da) 2019-11-25 2020-11-25 Substituerede makrocykliske forbindelser og relaterede behandlingsfremgangsmåder
KR1020227021501A KR20220106793A (ko) 2019-11-25 2020-11-25 치환된 마크로사이클릭 화합물 및 관련 치료 방법
IL293240A IL293240B2 (en) 2019-11-25 2020-11-25 Transforming macrocyclic compounds, compositions containing them and uses thereof
EP20828463.8A EP4065585B1 (en) 2019-11-25 2020-11-25 Substituted macrocyclic compounds and related methods of treatment
JP2022529454A JP7787812B2 (ja) 2019-11-25 2020-11-25 置換大環状化合物および関連する治療方法
SI202030661T SI4065585T1 (sl) 2019-11-25 2020-11-25 Substituirane makrociklične spojine ter z njimi povezani postopki zdravljenja
MDE20221089T MD4065585T2 (ro) 2019-11-25 2020-11-25 Compuși macrociclici substituiți și metode de tratament asociate
FIEP20828463.8T FI4065585T3 (fi) 2019-11-25 2020-11-25 Substituoituja makrosyklisiä yhdisteitä ja niihin liittyviä hoitomenetelmiä
MA57908A MA57908B1 (fr) 2019-11-25 2020-11-25 Composés macrocycliques substitués et méthodes de traitement associées
MX2022006206A MX2022006206A (es) 2019-11-25 2020-11-25 Compuestos macrociclicos sustituidos y metodos de tratamiento relacionados.
HRP20251156TT HRP20251156T1 (hr) 2019-11-25 2020-11-25 Supstituirani makrociklični spojevi i srodni postupci liječenja
BR112022009938A BR112022009938A2 (pt) 2019-11-25 2020-11-25 Compostos macrocíclicos substituídos e métodos de tratamento relacionados
IL320038A IL320038A (en) 2019-11-25 2020-11-25 Substituted macrocyclic compounds compositions comprising same and uses thereof
CA3155885A CA3155885A1 (en) 2019-11-25 2020-11-25 Substituted macrocyclic compounds and related methods of treatment
SM20250340T SMT202500340T1 (it) 2019-11-25 2020-11-25 Composti macrociclici sostituiti e metodi di trattamento correlati
ES20828463T ES3041424T3 (en) 2019-11-25 2020-11-25 Substituted macrocyclic compounds and related methods of treatment
NZ787541A NZ787541B2 (en) 2020-11-25 Substituted macrocyclic compounds and related methods of treatment
LTEPPCT/US2020/062320T LT4065585T (lt) 2019-11-25 2020-11-25 Pakeistieji makrocikliniai junginiai ir susiję gydymo būdai
SA522432691A SA522432691B1 (ar) 2019-11-25 2022-05-23 المركبات الحلقية الماكروية وطرق العلاج المرتبطة بها
ZA2022/06482A ZA202206482B (en) 2019-11-25 2022-06-10 Substituted macrocyclic compounds and related methods of treatment
AU2025203295A AU2025203295A1 (en) 2019-11-25 2025-05-07 Substituted macrocyclic compounds and related methods of treatment
JP2025141156A JP2025186272A (ja) 2019-11-25 2025-08-27 置換大環状化合物および関連する治療方法

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962939825P 2019-11-25 2019-11-25
US62/939,825 2019-11-25
US202063030979P 2020-05-28 2020-05-28
US63/030,979 2020-05-28

Publications (1)

Publication Number Publication Date
WO2021108628A1 true WO2021108628A1 (en) 2021-06-03

Family

ID=73856348

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2020/062320 Ceased WO2021108628A1 (en) 2019-11-25 2020-11-25 Substituted macrocyclic compounds and related methods of treatment

Country Status (25)

Country Link
US (3) US11542276B2 (https=)
EP (2) EP4628167A3 (https=)
JP (2) JP7787812B2 (https=)
KR (1) KR20220106793A (https=)
CN (1) CN114761412B (https=)
AU (2) AU2020394444B2 (https=)
BR (1) BR112022009938A2 (https=)
CA (1) CA3155885A1 (https=)
DK (1) DK4065585T3 (https=)
ES (1) ES3041424T3 (https=)
FI (1) FI4065585T3 (https=)
HR (1) HRP20251156T1 (https=)
HU (1) HUE073461T2 (https=)
IL (2) IL293240B2 (https=)
LT (1) LT4065585T (https=)
MA (1) MA57908B1 (https=)
MD (1) MD4065585T2 (https=)
MX (1) MX2022006206A (https=)
PT (1) PT4065585T (https=)
RS (1) RS67202B1 (https=)
SA (1) SA522432691B1 (https=)
SI (1) SI4065585T1 (https=)
SM (1) SMT202500340T1 (https=)
WO (1) WO2021108628A1 (https=)
ZA (1) ZA202206482B (https=)

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022051583A1 (en) * 2020-09-03 2022-03-10 Orexia Therapeutics Limited Medium- or macro-cyclic benzyl-substituted heterocycle derivatives and their uses as orexin-2 receptor agonists
WO2022109117A1 (en) * 2020-11-23 2022-05-27 Merck Sharp & Dohme Corp. 3-amino pyrrolidine and piperidine macrocyclic orexin receptor agonists
WO2022140316A1 (en) * 2020-12-21 2022-06-30 Alkermes, Inc. Substituted macrocyclic compounds and related methods of treatment
WO2022232025A1 (en) * 2021-04-26 2022-11-03 Alkermes, Inc. Substituted amide macrocyclic compounds with orexin-2 receptor agonist activity
WO2022251302A1 (en) * 2021-05-26 2022-12-01 Alkermes, Inc. Substituted fused bicyclic macrocyclic compounds and related methods of treatment
WO2022251304A1 (en) * 2021-05-26 2022-12-01 Alkerme, Inc. Substituted carbamate macrocyclic compounds and related methods of treatment
WO2023167925A1 (en) * 2022-03-01 2023-09-07 Orexia Therapeutics Limited Medium- or macro-cyclic benzyl-substituted heterocycle derivatives and related uses
WO2024095158A1 (en) 2022-10-31 2024-05-10 Takeda Pharmaceutical Company Limited Dosing of orexin type 2 receptor agonists
WO2024112899A1 (en) * 2022-11-23 2024-05-30 Vertex Pharmaceuticals Incorporated Substituted macrocyclic amine modulators of orexin receptor 2
WO2024128305A1 (ja) 2022-12-16 2024-06-20 第一三共株式会社 ２－アザビシクロ［３．１．１］ヘプタン化合物
US12054495B2 (en) 2019-11-25 2024-08-06 Alkermes, Inc. Substituted macrocyclic compounds and related methods of treatment
WO2024160822A1 (en) 2023-01-31 2024-08-08 Jazz Pharmaceuticals Ireland Limited Macrocyclic orexin receptor agonists and uses thereof
WO2024189597A1 (en) 2023-03-16 2024-09-19 Takeda Pharmaceutical Company Limited Macrocyclic heterocycle compounds and use thereof
WO2024246867A1 (en) 2023-06-02 2024-12-05 Takeda Pharmaceutical Company Limited Use of an orexin 2 receptor agonist for improving respiratory function during sleep
WO2024246285A1 (en) 2023-06-01 2024-12-05 H. Lundbeck A/S Spiromacrocyclic orexin 2 receptor agonists
WO2025096445A1 (en) 2023-10-30 2025-05-08 Alkermes, Inc. Synthesis of intermediates for the preparation of macrocyclic compounds
WO2025124698A1 (en) 2023-12-12 2025-06-19 Idorsia Pharmaceuticals Ltd Aryl sulfone and sulfanone derivatives as orexin receptor modulators
WO2025132542A1 (en) 2023-12-19 2025-06-26 Idorsia Pharmaceuticals Ltd Macrocyclic orexin agonists
US12441710B2 (en) 2020-12-21 2025-10-14 Alkermes, Inc. Substituted piperidino compounds and related methods of treatment
WO2025229493A1 (en) 2024-04-29 2025-11-06 Takeda Pharmaceutical Company Limited Dosing of orexin type 2 receptor agonists
US12503475B2 (en) 2020-09-03 2025-12-23 Centessa Pharmaceuticals (Uk) Limited Bicyclic-heterocycle derivatives and their uses as orexin-2 receptor agonists

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024361979A1 (en) * 2023-10-20 2026-03-05 Alkermes, Inc. Compound for use in treating narcolepsy
TW202547576A (zh) * 2024-04-04 2025-12-16 日商橘生藥品工業股份有限公司 取代磺醯胺巨環狀化合物
WO2025224168A1 (en) 2024-04-24 2025-10-30 Idorsia Pharmaceuticals Ltd Aryl sulfone and sulfanone derivatives as orexin receptor modulators
WO2026017128A1 (zh) * 2024-07-17 2026-01-22 江苏恩华药业股份有限公司 作为食欲素受体激动剂的环烯烃衍生物及其组合物和用途

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8258163B2 (en) 2008-06-04 2012-09-04 Board Of Regents, The University Of Texas System Small-molecule agonists for type-2 orexin receptor
WO2014198880A1 (en) 2013-06-14 2014-12-18 Ferrer Internacional, S.A. 2-(2-aminophenoxy)-3-chloronaphthalene-1,4-dione compounds having orexin 2 receptor agonist activity
WO2015048091A1 (en) 2013-09-24 2015-04-02 The Board Of Regents Of The University Of Texas System Orexin-control of bone formation and loss
WO2015073707A1 (en) 2013-11-15 2015-05-21 The Board Of Trustees Of The Leland Stanford Junior University Methods of treating heart failure with agonists of hypocretin receptor 2
WO2015088000A1 (ja) 2013-12-12 2015-06-18 国立大学法人筑波大学 スルホンアミド誘導体またはその薬学的に許容される酸付加塩
WO2015147240A1 (ja) 2014-03-28 2015-10-01 国立大学法人筑波大学 敗血症の予防治療剤
WO2017135306A1 (en) 2016-02-04 2017-08-10 Takeda Pharmaceutical Company Limited Substituted piperidine compound and use thereof
WO2019027058A1 (en) * 2017-08-03 2019-02-07 Takeda Pharmaceutical Company Limited HETEROCYCLIC COMPOUND AND USE THEREOF

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0939121B2 (de) 1989-09-12 2007-12-26 AHP Manufacturing B.V. TFN-bindende Proteine
US5635599A (en) 1994-04-08 1997-06-03 The United States Of America As Represented By The Department Of Health And Human Services Fusion proteins comprising circularly permuted ligands
EP1027373B1 (en) 1997-10-31 2006-09-06 Biomira, Inc. Muc-1 derivatives and their use in treating cancer-associated muc-1 mucin-induced immunosuppression
WO1999046392A1 (en) 1998-03-12 1999-09-16 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions of chemokine-tumor antigen fusion proteins as cancer vaccines
EP1066322A1 (en) 1998-04-03 2001-01-10 The University of Washington Circularly permuted biotin binding proteins
WO2000029447A1 (en) 1998-11-19 2000-05-25 Smithkline Beecham Corporation Rhamm antagonist antibodies
US6428985B1 (en) 1998-12-02 2002-08-06 The Regents Of The University Of Michigan Immunosuppressive structural definition of IL-10
US7754855B1 (en) 1999-07-13 2010-07-13 Bolder Biotechnology, Inc. Immunoglobulin fusion proteins
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
CA2391080A1 (en) 1999-11-12 2001-05-25 Merck Patent Gesellschaft Mit Beschraenkter Haftung Erythropoietin forms with improved properties
WO2001058950A1 (en) 2000-02-11 2001-08-16 Maxygen Aps Improved interleukin 10
EP1272467A4 (en) 2000-04-06 2003-05-07 Merck Frosst Canada Inc Cathepsin cysteine protease inhibitors
IL155812A0 (en) 2000-12-07 2003-12-23 Lilly Co Eli Glp-1 fusion proteins
JP2004519230A (ja) 2001-02-06 2004-07-02 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 低減された免疫原性を有する修飾されたインターロイキン−１受容体アンタゴニスト（ｉｌ−１ｒａ）
CA2454469A1 (en) 2001-07-20 2003-02-06 Absorber, Ab Blood group antigen fusion polypeptides and methods of use thereof
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
EP1534748A2 (en) 2002-08-09 2005-06-01 Recopharma AB Fusion proteins and methods of producing same
AU2003280315A1 (en) 2002-11-14 2004-06-03 Maxygen, Inc. Conjugates of interleukin-10 and polymers
WO2004060911A2 (en) 2002-12-30 2004-07-22 Amgen Inc. Combination therapy with co-stimulatory factors
PL2298347T3 (pl) 2003-05-06 2016-03-31 Bioverativ Therapeutics Inc Białka chimeryczne czynnika krzepnięcia do leczenia zaburzenia hemostazy
US7696322B2 (en) 2003-07-28 2010-04-13 Catalent Pharma Solutions, Inc. Fusion antibodies
US20150071948A1 (en) 2003-09-26 2015-03-12 Gregory Alan Lazar Novel immunoglobulin variants
WO2005034863A2 (en) 2003-10-03 2005-04-21 Jarikuma Corporation Countermeasures against malaria
WO2005042573A1 (en) 2003-10-24 2005-05-12 Dana-Farber Cancer Institute, Inc. Modulation of the interaction of muc1 with muc1 ligands
US8454963B2 (en) 2003-11-13 2013-06-04 Musc Foundation For Research Development Tissue targeted complement modulators
US7576183B2 (en) 2003-12-24 2009-08-18 Los Alamos National Security, Llc Structure-based receptor MIMICS targeted against bacterial superantigen toxins
CA2583983C (en) 2004-10-14 2013-07-16 Abbott Gmbh & Co. Kg Heterocyclic compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor
MX2007006214A (es) 2004-11-24 2008-04-16 Therakine Ltd Un implante para suministro de farmaco intraocular.
CN101163477A (zh) 2005-02-23 2008-04-16 普雷萨药品公司 多介质多巴胺转运抑制剂，以及其相关应用
CA2618791C (en) 2005-08-12 2014-05-13 Riken Novel mucin-type glycoprotein and use thereof
US20100016547A1 (en) 2005-11-30 2010-01-21 Takaomi Ito Glycosilated Peptide and Medicine Comprising It as an Effective Ingredient
DE602005015733D1 (de) 2005-12-02 2009-09-10 Apceth Gmbh & Co Kg Chemokin-Mucin Fusionsproteine mit einer GPI-Ankerdomäne und deren Verwendung als Tumor-Immun-Adjuvanzien oder in der Geweberegeneration
WO2008140595A2 (en) 2006-12-01 2008-11-20 President And Fellows Of Harvard College Synthetic trivalent haptens, complexes thereof, and uses therefor
WO2008133928A2 (en) 2007-04-27 2008-11-06 The Gi Company, Inc. Mucin glycoproteins and their use for treatment of epithelial lesions and mucin dependent disorders
JP2010536341A (ja) 2007-08-15 2010-12-02 アムニクス， インコーポレイテッド 生物学的に活性なポリペプチドの特性を改変するための組成物および方法
US8765669B2 (en) 2008-06-17 2014-07-01 Glytech, Inc. Glycosylated GLP-1 peptide
ES2411916T3 (es) 2008-08-14 2013-07-09 Janssen R&D Ireland Derivados indólicos macrocíclicos útiles como inhibidores del virus de la hepatitis c
EP3028707A1 (en) 2009-05-01 2016-06-08 Ophthotech Corporation Methods for treating or preventing ophthalmological diseases
BRPI1014583B1 (pt) 2009-06-26 2020-03-31 Pfizer, Inc. Sulfonamidas heterocíclicas e composições farmacêuticas
BR112012017164A2 (pt) 2009-12-22 2019-09-24 Novartis Ag proteína de fusão de região constante de anticorpo-cd47 tetravalente
CA2785907A1 (en) 2009-12-29 2011-07-28 Emergent Product Development Seattle, Llc Ron binding constructs and methods of use thereof
AR080993A1 (es) 2010-04-02 2012-05-30 Hanmi Holdings Co Ltd Formulacion de accion prolongada de interferon beta donde se usa un fragmento de inmunoglobulina
CN101962413B (zh) 2010-09-21 2013-03-13 中国科学技术大学 具有透皮能力和白细胞介素-10活性的融合蛋白及其编码基因与应用
US8883134B2 (en) 2010-10-20 2014-11-11 Handok Pharmaceuticals, Inc. Human interleukin-1 receptor antagonist—hybrid Fc fusion protein
EP2457579A1 (en) 2010-11-26 2012-05-30 Technische Universität Dresden Covalently linked interleukin -10
TWI743461B (zh) 2011-03-28 2021-10-21 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
EP2694472B1 (en) 2011-04-05 2020-03-11 Takeda Pharmaceutical Company Limited Sulfonamide derivative and use thereof
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
EP2723380B1 (en) 2011-06-24 2019-08-21 Stephen D. Gillies Light chain immunoglobulin fusion proteins and methods of use thereof
NO2748201T3 (https=) 2011-08-23 2018-05-12
US10017481B2 (en) 2012-03-17 2018-07-10 Polyphor Ag Conformationally constrained, fully synthetic macrocyclic compounds
US9062120B2 (en) 2012-05-02 2015-06-23 Janssen Biotech, Inc. Binding proteins having tethered light chains
EP2851429B1 (en) 2012-05-18 2019-07-24 Adda Biotech Inc. Protein and protein conjugate for diabetes treatment, and applications thereof
US9156897B2 (en) 2012-06-08 2015-10-13 Alkermes, Inc. Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide
IN2015DN01299A (https=) 2012-07-23 2015-07-03 Zymeworks Inc
PE20150645A1 (es) 2012-08-08 2015-05-11 Roche Glycart Ag Proteinas de fusion de interleuquina 10 y usos de las mismas
US11634502B2 (en) 2013-03-15 2023-04-25 Amgen Inc. Heterodimeric bispecific antibodies
EP2989240A4 (en) 2013-04-24 2016-10-19 Armo Biosciences Inc INTERLEUKIN-10 COMPOSITIONS AND USES THEREOF
CA2919076C (en) 2013-07-31 2024-01-30 Amgen Inc. Stabilization of fc-containing polypeptides
WO2015117930A1 (en) 2014-02-06 2015-08-13 F. Hoffmann-La Roche Ag Interleukine 10 immunoconjugates
KR102455043B1 (ko) 2014-09-11 2022-10-13 얀센 파마슈티카 엔.브이. 치환된 2-아자바이사이클 및 오렉신 수용체 조절제로서의 이의 용도
CN104403004B (zh) 2014-11-24 2017-10-13 苏州丁孚靶点生物技术有限公司 抗体‑干扰素异二聚体的制备和用途
AU2015364396B2 (en) 2014-12-19 2018-08-09 Alkermes, Inc. Single chain Fc fusion proteins
WO2016101119A1 (en) * 2014-12-23 2016-06-30 Merck Sharp & Dohme Corp. Fused heteroaryl derivatives as orexin receptor antagonists
WO2016133160A1 (ja) 2015-02-19 2016-08-25 国立大学法人筑波大学 スルホンアミド誘導体またはその薬学的に許容される酸付加塩
WO2016199906A1 (ja) 2015-06-12 2016-12-15 国立大学法人筑波大学 スルホンアミド誘導体またはその薬学的に許容される酸付加塩
CN107787322B (zh) * 2015-06-17 2023-07-07 辉瑞大药厂 三环化合物以及它们作为磷酸二酯酶抑制剂的用途
BR112018003588A2 (pt) * 2015-08-26 2018-09-25 Blueprint Medicines Corp compostos e composições úteis para tratamento de distúrbios relacionados ao ntrk
CN108699065B (zh) * 2015-12-18 2021-08-31 诺华股份有限公司 作为激酶抑制剂的三环类化合物和组合物
WO2017165464A1 (en) 2016-03-21 2017-09-28 Elstar Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
WO2018005226A2 (en) 2016-06-22 2018-01-04 Alkermes, Inc. Compositions and methods for modulating il-10 immunostimulatory and anti-inflammatory properties
WO2018164191A1 (ja) 2017-03-08 2018-09-13 武田薬品工業株式会社 置換ピロリジン化合物およびその用途
US11034700B2 (en) 2017-03-08 2021-06-15 Takeda Pharmaceutical Company Limited Substituted pyrrolidine compound and use thereof
US11319286B2 (en) 2017-08-03 2022-05-03 Takeda Pharmaceutical Company Limited Heterocyclic compound and application thereof
CN111132975B (zh) 2017-09-28 2023-05-23 勃林格殷格翰国际有限公司 N-(2,2-二氟乙基)-n-[(嘧啶基氨基)丙基]芳基甲酰胺
WO2019117148A1 (ja) 2017-12-12 2019-06-20 国立大学法人 筑波大学 スルホンアミド誘導体またはその薬学的に許容される酸付加塩
MX2020010155A (es) 2018-03-27 2021-03-25 Univ Texas Compuestos de ox2r.
US12077522B2 (en) 2018-06-29 2024-09-03 Takeda Pharmaceutical Company Limited Heterocyclic compound and application thereof
JP7413261B2 (ja) 2018-06-29 2024-01-15 武田薬品工業株式会社 複素環化合物およびその用途
EP3896060B1 (en) 2018-12-12 2023-08-16 Takeda Pharmaceutical Company Limited Heterocyclic compound
JP7379374B2 (ja) 2018-12-12 2023-11-14 武田薬品工業株式会社 複素環化合物
SG11202106791XA (en) 2019-01-31 2021-07-29 Takeda Pharmaceuticals Co Heterocyclic compound and use thereof
WO2020167701A1 (en) 2019-02-13 2020-08-20 Merck Sharp & Dohme Corp. Pyrrolidine orexin receptor agonists
US11098029B2 (en) 2019-02-13 2021-08-24 Merck Sharp & Dohme Corp. 5-alkyl pyrrolidine orexin receptor agonists
WO2021026047A1 (en) 2019-08-08 2021-02-11 Merck Sharp & Dohme Corp. Heteroaryl pyrrolidine and piperidine orexin receptor agonists
BR112022004576A2 (pt) 2019-09-13 2022-06-14 Takeda Pharmaceuticals Co Métodos para diminuir ou tratar sonolência excessiva, tratar narcolepsia tipo 2 ou hipersonia idiopática, tratar distúrbio de trabalho de turno, aumentar latência de sono em manutenção de teste de insônia, melhorar classificação de escaça de sonolência de karolinska, diminuir ou melhorar sonolência subjetiva, aumentar insônia ou diminuir sonolência excessiva, melhorar classificação de escala de sonolência epworth, tratar narcolepsia tipo 2, diminuir ou tratar sonolência diurna excessiva, e, composição farmacêutica
FI4065585T3 (fi) 2019-11-25 2025-09-26 Alkermes Inc Substituoituja makrosyklisiä yhdisteitä ja niihin liittyviä hoitomenetelmiä
US11352357B2 (en) 2019-11-27 2022-06-07 Sumitomo Dainippon Pharma Co., Ltd. Cycloalkylurea derivative
WO2021106975A1 (ja) 2019-11-27 2021-06-03 武田薬品工業株式会社 複素環化合物
MX2022008392A (es) 2020-01-10 2022-08-08 Takeda Pharmaceuticals Co Metodo para mejorar la farmacocinetica o aumentar la concentracion de plasma de 3-((metilsulfonil)amino)-2-(((4-fenilci clohexil)oxi)metil)piperidina-1-carboxilato de metilo o una sal del mismo con un inhibidor de citocromo p450.
KR20230040953A (ko) 2020-07-17 2023-03-23 에자이 알앤드디 매니지먼트 가부시키가이샤 치환된 피페리딘 화합물 및 이의 적용례
BR112023002957A2 (pt) 2020-08-18 2023-04-04 Merck Sharp & Dohme Llc Composto, composição farmacêutica, e, métodos para tratar narcolepsia e para tratar hipersonia em um sujeito mamífero
EP4199925A4 (en) 2020-08-18 2024-08-28 Merck Sharp & Dohme LLC CYCLOPENTAPYRROLE OREXIN RECEPTOR AGONISTS
US12503475B2 (en) 2020-09-03 2025-12-23 Centessa Pharmaceuticals (Uk) Limited Bicyclic-heterocycle derivatives and their uses as orexin-2 receptor agonists
WO2022051583A1 (en) 2020-09-03 2022-03-10 Orexia Therapeutics Limited Medium- or macro-cyclic benzyl-substituted heterocycle derivatives and their uses as orexin-2 receptor agonists
JP2022064180A (ja) 2020-10-13 2022-04-25 武田薬品工業株式会社 複素環化合物
EP4236938A4 (en) 2020-11-02 2024-10-16 Merck Sharp & Dohme LLC MACROCYCLIC UREA-OREX RECEPTOR AGONISTS
WO2022109117A1 (en) 2020-11-23 2022-05-27 Merck Sharp & Dohme Corp. 3-amino pyrrolidine and piperidine macrocyclic orexin receptor agonists
EP4255429A4 (en) 2020-12-03 2024-12-11 Merck Sharp & Dohme LLC 3-heteroaryl pyrrolidine and piperidine orexin receptor agonists
US20240101555A1 (en) 2020-12-16 2024-03-28 Merck Sharp & Dohme Llc Urea orexin receptor agonists
US12006330B2 (en) 2020-12-21 2024-06-11 Alkermes, Inc. Substituted macrocyclic compounds and related methods of treatment
US11760747B2 (en) 2020-12-21 2023-09-19 Alkermes, Inc. Substituted piperidino compounds and related methods of treatment
US20240174605A1 (en) 2021-03-03 2024-05-30 Research Triangle Institute Arylsulfonamides as orexin receptor agonists
WO2022207935A1 (en) 2021-04-02 2022-10-06 Orexia Therapeutics Limited 2-(3-ethynylbenzyl)-substituted heterocycle derivatives as orexin-2 agonists
KR20240004802A (ko) 2021-05-03 2024-01-11 재즈 파마슈티칼즈 아일랜드 리미티드 오렉신 수용체 효능제 및 그의 용도

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8258163B2 (en) 2008-06-04 2012-09-04 Board Of Regents, The University Of Texas System Small-molecule agonists for type-2 orexin receptor
WO2014198880A1 (en) 2013-06-14 2014-12-18 Ferrer Internacional, S.A. 2-(2-aminophenoxy)-3-chloronaphthalene-1,4-dione compounds having orexin 2 receptor agonist activity
WO2015048091A1 (en) 2013-09-24 2015-04-02 The Board Of Regents Of The University Of Texas System Orexin-control of bone formation and loss
WO2015073707A1 (en) 2013-11-15 2015-05-21 The Board Of Trustees Of The Leland Stanford Junior University Methods of treating heart failure with agonists of hypocretin receptor 2
WO2015088000A1 (ja) 2013-12-12 2015-06-18 国立大学法人筑波大学 スルホンアミド誘導体またはその薬学的に許容される酸付加塩
WO2015147240A1 (ja) 2014-03-28 2015-10-01 国立大学法人筑波大学 敗血症の予防治療剤
WO2017135306A1 (en) 2016-02-04 2017-08-10 Takeda Pharmaceutical Company Limited Substituted piperidine compound and use thereof
US20170226137A1 (en) 2016-02-04 2017-08-10 Takeda Pharmaceutical Company Limited Substituted piperidine compound and use thereof
US20190031611A1 (en) 2016-02-04 2019-01-31 Takeda Pharmaceutical Company Limited Substituted piperidine compound and use thereof
WO2019027058A1 (en) * 2017-08-03 2019-02-07 Takeda Pharmaceutical Company Limited HETEROCYCLIC COMPOUND AND USE THEREOF
US20190040010A1 (en) 2017-08-03 2019-02-07 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof

Non-Patent Citations (22)

* Cited by examiner, † Cited by third party
Title
"Larock's Comprehensive Organic Transformations", vol. 1-5, 1989, ELSEVIER SCIENCE PUBLISHERS
"Remington's Pharmaceutical Sciences", 1985, MACK PUBLISHING COMPANY, pages: 1418
BRAIN, vol. 130, 2007, pages 1586 - 1595
CAREYSUNDBERG: "Advanced Organic Chemistry", 2000, PLENUM
CELL METABOLISM, vol. 9, 2009, pages 64 - 76
CELL, vol. 92, 1998, pages 573 - 585
CELL, vol. 98, 1999, pages 437 - 451
CNS DRUGS, vol. 27, 2013, pages 83 - 90
DAVIES B.MORRIS T.: "Physiological Parameters in Laboratory Animals and Humans", PHARMARES, vol. 10, no. 7, 1993, pages 1093 - 1095
FIESERFIESER: "Reagents for Organic Synthesis", vol. 1-40, 1991, JOHN WILEY AND SONS
GREENWUTS: "Protective Groups in Organic Synthesis", 1999, WILEY
JOURNAL OF MEDICINAL CHEMISTRY, vol. 58, pages 7931 - 7937
JOURNAL OF PHARMACEUTICAL SCIENCE, vol. 66, 1977, pages 2
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, vol. 66, 2015, pages 2522 - 2533
MAHONEY ET AL., NATURE REVIEWS NEUROSCIENCE, 2019
NEUROSCIENCE, vol. 121, 2003, pages 855 - 863
PEPTIDES, vol. 23, 2002, pages 1683 - 1688
PROC. NATI, ACAD. SCI. USA, vol. 101, 2004, pages 4649 - 4654
RESPIRATION, vol. 71, 2004, pages 575 - 579
SAKURAI, NATURE REVIEWS NEUROSCIENCE, 2014
SAPER ET AL., TRENDS IN NEUROSCIENCE, 2001
YAMANAKA ET AL., NEURON, vol. 38, 2003, pages 715 - 730

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12054495B2 (en) 2019-11-25 2024-08-06 Alkermes, Inc. Substituted macrocyclic compounds and related methods of treatment
WO2022051583A1 (en) * 2020-09-03 2022-03-10 Orexia Therapeutics Limited Medium- or macro-cyclic benzyl-substituted heterocycle derivatives and their uses as orexin-2 receptor agonists
US12503475B2 (en) 2020-09-03 2025-12-23 Centessa Pharmaceuticals (Uk) Limited Bicyclic-heterocycle derivatives and their uses as orexin-2 receptor agonists
WO2022109117A1 (en) * 2020-11-23 2022-05-27 Merck Sharp & Dohme Corp. 3-amino pyrrolidine and piperidine macrocyclic orexin receptor agonists
CN116615427A (zh) * 2020-12-21 2023-08-18 阿尔克姆斯有限公司 被取代的大环化合物及相关治疗方法
CN116615427B (zh) * 2020-12-21 2025-07-04 阿尔克姆斯有限公司 被取代的大环化合物及相关治疗方法
WO2022140316A1 (en) * 2020-12-21 2022-06-30 Alkermes, Inc. Substituted macrocyclic compounds and related methods of treatment
US12441710B2 (en) 2020-12-21 2025-10-14 Alkermes, Inc. Substituted piperidino compounds and related methods of treatment
US12006330B2 (en) 2020-12-21 2024-06-11 Alkermes, Inc. Substituted macrocyclic compounds and related methods of treatment
WO2022232025A1 (en) * 2021-04-26 2022-11-03 Alkermes, Inc. Substituted amide macrocyclic compounds with orexin-2 receptor agonist activity
WO2022251304A1 (en) * 2021-05-26 2022-12-01 Alkerme, Inc. Substituted carbamate macrocyclic compounds and related methods of treatment
WO2022251302A1 (en) * 2021-05-26 2022-12-01 Alkermes, Inc. Substituted fused bicyclic macrocyclic compounds and related methods of treatment
WO2023167925A1 (en) * 2022-03-01 2023-09-07 Orexia Therapeutics Limited Medium- or macro-cyclic benzyl-substituted heterocycle derivatives and related uses
WO2024095158A1 (en) 2022-10-31 2024-05-10 Takeda Pharmaceutical Company Limited Dosing of orexin type 2 receptor agonists
WO2024112899A1 (en) * 2022-11-23 2024-05-30 Vertex Pharmaceuticals Incorporated Substituted macrocyclic amine modulators of orexin receptor 2
WO2024128305A1 (ja) 2022-12-16 2024-06-20 第一三共株式会社 ２－アザビシクロ［３．１．１］ヘプタン化合物
EP4635944A1 (en) 2022-12-16 2025-10-22 Daiichi Sankyo Company, Limited 2-azabicyclo[3.1.1]heptane compound
KR20250112793A (ko) 2022-12-16 2025-07-24 다이이찌 산쿄 가부시키가이샤 2-아자비시클로[3.1.1]헵탄 화합물
WO2024160822A1 (en) 2023-01-31 2024-08-08 Jazz Pharmaceuticals Ireland Limited Macrocyclic orexin receptor agonists and uses thereof
WO2024189597A1 (en) 2023-03-16 2024-09-19 Takeda Pharmaceutical Company Limited Macrocyclic heterocycle compounds and use thereof
WO2024246285A1 (en) 2023-06-01 2024-12-05 H. Lundbeck A/S Spiromacrocyclic orexin 2 receptor agonists
US12590106B2 (en) * 2023-06-01 2026-03-31 H. Lundbeck A/S Spiromacrocyclic orexin 2 receptor agonists
WO2024246867A1 (en) 2023-06-02 2024-12-05 Takeda Pharmaceutical Company Limited Use of an orexin 2 receptor agonist for improving respiratory function during sleep
WO2025096445A1 (en) 2023-10-30 2025-05-08 Alkermes, Inc. Synthesis of intermediates for the preparation of macrocyclic compounds
WO2025124698A1 (en) 2023-12-12 2025-06-19 Idorsia Pharmaceuticals Ltd Aryl sulfone and sulfanone derivatives as orexin receptor modulators
WO2025132542A1 (en) 2023-12-19 2025-06-26 Idorsia Pharmaceuticals Ltd Macrocyclic orexin agonists
WO2025229493A1 (en) 2024-04-29 2025-11-06 Takeda Pharmaceutical Company Limited Dosing of orexin type 2 receptor agonists

Also Published As

Publication number Publication date
JP7787812B2 (ja) 2025-12-17
EP4065585A1 (en) 2022-10-05
MA57908B1 (fr) 2025-09-30
AU2020394444B2 (en) 2025-05-29
PT4065585T (pt) 2025-09-30
SMT202500340T1 (it) 2025-11-10
EP4628167A3 (en) 2025-12-03
US20210155636A1 (en) 2021-05-27
HRP20251156T1 (hr) 2025-11-21
ZA202206482B (en) 2025-10-29
JP2023502441A (ja) 2023-01-24
KR20220106793A (ko) 2022-07-29
LT4065585T (lt) 2025-10-10
MD4065585T2 (ro) 2025-12-31
EP4065585B1 (en) 2025-08-20
HUE073461T2 (hu) 2026-01-28
CN114761412B (zh) 2024-10-11
DK4065585T3 (da) 2025-09-08
US20250092063A1 (en) 2025-03-20
FI4065585T3 (fi) 2025-09-26
BR112022009938A2 (pt) 2022-09-13
SA522432691B1 (ar) 2025-05-27
IL320038A (en) 2025-06-01
ES3041424T3 (en) 2025-11-12
RS67202B1 (sr) 2025-10-31
US12054495B2 (en) 2024-08-06
CA3155885A1 (en) 2021-06-03
IL293240B1 (en) 2025-05-01
US20230339969A1 (en) 2023-10-26
NZ787541A (en) 2025-10-31
IL293240A (en) 2022-07-01
US11542276B2 (en) 2023-01-03
SI4065585T1 (sl) 2025-11-28
JP2025186272A (ja) 2025-12-23
IL293240B2 (en) 2025-09-01
MX2022006206A (es) 2022-09-09
AU2025203295A1 (en) 2025-05-29
EP4628167A2 (en) 2025-10-08
AU2020394444A1 (en) 2022-05-19
CN114761412A (zh) 2022-07-15

Similar Documents

Publication Publication Date Title
EP4065585B1 (en) Substituted macrocyclic compounds and related methods of treatment
US12006330B2 (en) Substituted macrocyclic compounds and related methods of treatment
AU2021409664A9 (en) Substituted piperidino compounds and related methods of treatment
AU2022267220A1 (en) Substituted amide macrocyclic compounds with orexin-2 receptor agonist activity
HK40129946A (en) Substituted macrocyclic compounds and related methods of treatment
HK40079289A (en) Substituted macrocyclic compounds and related methods of treatment
HK40079289B (en) Substituted macrocyclic compounds and related methods of treatment
EA047646B1 (ru) Замещенные макроциклические соединения и связанные с ними способы лечения
EA049565B1 (ru) Замещенные макроциклические соединения, обладающие активностью агониста рецептора орексина-2, и их применение
HK40099265A (en) Substituted piperidino compounds and related methods of treatment
HK40099265B (en) Substituted piperidino compounds and related methods of treatment

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20828463

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3155885

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2020394444

Country of ref document: AU

Date of ref document: 20201125

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2022529454

Country of ref document: JP

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112022009938

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 20227021501

Country of ref document: KR

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2020828463

Country of ref document: EP

Effective date: 20220627

ENP Entry into the national phase

Ref document number: 112022009938

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20220520

WWE Wipo information: entry into national phase

Ref document number: 522432691

Country of ref document: SA

WWE Wipo information: entry into national phase

Ref document number: 522432691

Country of ref document: SA

WWE Wipo information: entry into national phase

Ref document number: 522432691

Country of ref document: SA

WWD Wipo information: divisional of initial pct application

Ref document number: 320038

Country of ref document: IL

WWG Wipo information: grant in national office

Ref document number: 522432691

Country of ref document: SA

WWG Wipo information: grant in national office

Ref document number: 11202204456X

Country of ref document: SG

WWG Wipo information: grant in national office

Ref document number: 2020828463

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: MX/A/2022/006206

Country of ref document: MX

WWG Wipo information: grant in national office

Ref document number: 787541

Country of ref document: NZ

WWD Wipo information: divisional of initial pct application

Ref document number: 202648017025

Country of ref document: IN

WWG Wipo information: grant in national office

Ref document number: 202247035891

Country of ref document: IN

WWP Wipo information: published in national office

Ref document number: 202648017025

Country of ref document: IN